Modulation of transcription factor EB activity by n-acetyl leucine to treat disorders
N-acetyl leucine modulates TFEB activity and calcium signaling to address the pathogenesis of metabolic, neurodegenerative, neurodevelopmental, and neurological disorders, enhancing lysosomal function and autophagy.
Patent Information
- Application Number
- PCT/US2026/027233
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-08-12
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
There is a need for effective small-molecule modulators to regulate TFEB activity and calcium signaling to prevent or reverse the pathogenesis of metabolic, neurodegenerative, neurodevelopmental, and neurological disorders, as well as cancer and defective autophagy diseases.
Administration of N-acetyl leucine to regulate TFEB activity, stimulate its translocation, and modulate lysosomal calcium levels to restore normal calcium signaling in cells.
N-acetyl leucine enhances lysosomal biogenesis, autophagy, and normalizes lysosomal calcium levels, providing therapeutic benefits for various disorders by improving cellular health and function.
Smart Images

Figure IMGF000053_0001 
Figure IMGF000053_0002 
Figure IMGF000012_0001_TABLE
Abstract
Description
MODULATION OF TRANSCRIPTION FACTOR EB ACTIVITY BYN-ACETYL LEUCINE TO TREAT DISORDERS REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0001] The content of the electronically submitted sequence listing in. XML file (File Name: 3999_054PC02_Sequencelisting_ST26; Size: 11,725 bytes; Date of Creation: April 30, 2026) filed with the application is incorporated herein by reference in its entirety.BACKGROUNDField
[0002] The present disclosure provides methods of modulating transcription factor EB (TFEB) activity, modulating lysosomal calcium levels, and / or normalizing calcium signaling in a cell of a subject, wherein the cell is contacted by an effective amount of N-acetyl leucine. These methods may be used to treat or prevent a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease and / or a clinical manifestation, e.g., symptom, thereof, in the subject.Background
[0003] TFEB contains basic helix-loop-helix-leucine zipper domains (bHLH-Zip) and belongs to the microphthalmia MIT-TFE family of transcription factors. Puertollano et al., EMBO J. 2018, 37, e98804. In its inactive state, TFEB resides in the cytoplasm; upon activation, it translocates to the nucleus to regulate gene expression. Dysregulation of TFEB activity is therefore implicated in various disorders, e.g. metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, or a neurological disorder, and cancer. Zhu et al., Medicine (Baltimore) 2022 101(50)'. e31870. Dysregulation of TFEB activity has also been implicated in kidney diseases, e.g., cystinosis, acute kidney injury, and diabetic nephropathy. Zhang et al., Cell Death Discov. 6, 32 (2020). doi.org / 10.1038 / s41420-020-0265-4. Previous studies have demonstrated that targeting the TFEB pathway has neuroprotective effects in various in vivo or in vitro models of Alzheimer's disease. Hence, small-molecule TFEB activators or exogenouslyoverexpressed TFEB may be essential, and promote the overall autophagic flux and may prevent, obstruct, or reverse the pathogenesis of neurodegenerative diseases. Gu et al., Neurobiol. Dis. 2022, 173, 105855-105855.
[0004] TFEB translocation to the nucleus is activated by dephosphorylation of specific serine moieties. In the nucleus, TFEB binds to regulatory sequences of DNA termed CLEAR (Coordinated Lysosomal Expression and Regulation), which regulates the expression of lysosomal and autophagic genes. Palmieri et al., Hum. Mol. Genet. 2011, 20, 3852-3866. This leads to an increase in lysosomal biogenesis and increased lysosomal function as well as enhancement of autophagy. Napolitano and Ballabio, J. Cell Sci. 2016, 129, 2475-2481.
[0005] In the cytoplasm, TFEB is phosphorylated by the mTOR complex, and this promotes its interaction with 14-3-3 proteins, which promotes its retention in the cytoplasm. Rosenbaum and Maxfield, J. Neurochem. 2011, 116, 789-795. Ca2+release from the lysosome via TPCs or TRPML1 channels activates the Ca2+-sensitive protein phosphatase calcineurin, which dephosphorylates TFEB, promoting its dissociation from 14-3-3 proteins and its translocation to the nucleus. Hoglinger et al., eLife 2015, 4, el0616; Medina et al., Nat. Cell Biol. 2015, 17, 288-299; Davis et al., EMBOJ. 2020, 39, el04058. Here, it binds to CLEAR sequences to activate lysosomal protein expression. Medina et al., Nat. Cell Biol. 2015, 17, 288-299. However, there is also significant bidirectional feedback between lysosomal Ca2+channels and mTOR. Ca2+release by TRPMLl activates calmodulin which associates with and activates mTOR. Li et al., eLife 2016, 5, el9360. In contrast, mTOR activation inhibits the opening of TPC2 channels, and mTOR-mediated phosphorylation of TRPMLl has been proposed to inhibit this channel. Onyenwoke et al., Biochem. J. 2015, 470, 331-342; Cang et al., Cell 2013, 152, 778-790. Indeed, mTOR inhibition by the allosteric antagonist rapamycin has been shown to stimulate lysosomal Ca2+release via TPC2. Ogunbayo et al., Sci. Signal. 2018, 11, eaao5775. However, in a reciprocal fashion, TPC2-evoked Ca2+release has also been proposed to activate mTOR. Chang et al., BMC Biol. 2020, 18, 8.
[0006] The mTOR complex is a major nutrient sensor in cells, sensing the metabolic status of the cell. It is recruited to the lysosome, where it senses amino acids transported from the lumen of the lysosome after protein degradation. Sancak et al., (2010) Cell, 141, 290-303; Zoncu et al., Science 2011, 334, 678-683. Leucine is the major activator of mTOR, and thiseffect is probably mediated by the protein sestrin, which is part of the mTOR signaling complex. Wolfson et al., Science 2016, 351, 43-48.
[0007] Lysosomes are calcium stores, and this calcium can be released by nicotinic acid adenine dinucleotide phosphate (NAADP), a Ca2+-mobilising intracellular messenger, evoking calcium signals that control specific cellular responses. Churchill et al., (2002) Cell 111, 703-708. The target for NAADP on the lysosome is a member of a novel family of lysosomal cation channels, the two-pore channel 2 (TPC2). Calcraft, et al., (2009) Nature 459, 596-600. Neurodegenerative disorders, e.g., Niemann-Pick disease type C (NPC), is associated with reduced levels of calcium in its lysosomes and impaired NAADP - evoked calcium release. Lloyd-Evans et al., (2008) Nat Med. 14: 1247-1255. These cellular defects are fundamental to the aetiology of NPC, given lysosomal calcium release is a major regulator of vesicular fusion, trafficking, autophagy, inflammasome priming and other key cellular responses, which all go awry in NPC. Morgan et al., (2011) Biochem. J. 439, 349-374.
[0008] Impaired lysosomal calcium levels have been identified in recent years to be critical to the pathophysiology of many neurodegenerative disorders. Feng and Yang, (2016) Messenger (Los Angel) 5, 56-66. Deficits in lysosomal Ca2+have been reported in genetic models of Parkinson’s disease, Kilpatrick et al., (2016). Cell Calcium 59, 12-20, and Alzheimer’s disease. Coen et al., (2012) J Cell Biol 198, 23-35.
[0009] There exists a need in the art for effective small-molecule TFEB modulators and calcium signaling modulators to prevent, obstruct, or reverse the pathogenesis of metabolic, neurodegenerative, neurodevel opmental, and neurological disorders, cancer, and defective autophagy diseases.BRIEF SUMMARY
[0010] In one aspect, the present disclosure provides a method of regulating TFEB activity in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject.
[0011] In another aspect, the present disclosure provides a method of regulating TFEB localization in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject.
[0012] In another aspect, the present disclosure provides a method of stimulating TFEB translocation from the cytoplasm of a cell to the nucleus of the cell in a subject in need thereof, the method comprising administering a therapeutically effective amount of N- acetyl leucine to the subject. In another aspect, the subject has a disorder, or a clinical manifestation thereof, wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, or a neurological disorder.
[0013] In another aspect, the present disclosure provides a method of modulating lysosomal calcium levels and / or calcium signaling in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject. In another aspect, the subject has a disorder, or a clinical manifestation thereof, wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, or a neurological disorder.
[0014] In another aspect, the present disclosure provides a method of treating or preventing a metabolic disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine (i) regulates the activity of TFEB, e.g., stimulates the translocation of TFEB from the cytoplasm of a cell to the nucleus of the cell depending on the basal nuclear TFEB in normal or if constitutively elevated in diseased cells; (ii) modulates the lysosomal calcium level; and / or (iii) restores normal calcium signaling, e.g., calcium homeostasis, in a cell of the subject.
[0015] In another aspect, the present disclosure provides a method of treating or preventing a neurodegenerative disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine (i) regulates the activity of TFEB, e.g., stimulates or reduces the translocation of TFEB from the cytoplasm of a cell to the nucleus of the cell depending on the basal nuclear TFEB in normal or if constitutively elevated in diseased cells; (ii) modulates the lysosomal calcium level; and / or (iii) restores normal calcium signaling, e.g., calcium homeostasis, in a cell of the subject.
[0016] In another aspect, the present disclosure provides a method of treating or preventing a neurodevelopmental disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount ofN-acetyl leucine to the subject, wherein the administering of N-acetyl leucine (i) stimulates the translocation of TFEB from the cytoplasm of a cell to the nucleus of the cell or from the nucleus to cytoplasm depending on the basal nuclear TFEB in normal or if constitutively elevated in diseased cells; (ii) modulates the lysosomal calcium level; and / or (iii) restores normal calcium signaling, e.g., calcium homeostasis, in a cell of the subject.
[0017] In another embodiment, the present disclosure provides a method of treating or preventing a neurological disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine (i) stimulates the translocation of TFEB from the cytoplasm of a cell to the nucleus of the cell or from the nucleus to cytoplasm depending on the basal nuclear TFEB in normal or if constitutively elevated in diseased cells; (ii) modulates the lysosomal calcium level; and / or (iii) restores normal calcium signaling, e.g., calcium homeostasis, in a cell of the subject.
[0018] It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only, and are not restrictive of the invention as claimed.BRIEF SUMMARY OF THE DRAWINGS
[0019] Fig. 1 is a bar graph showing the expression patterns of monocarboxylate transporters (MCT1, MCT2, MCT3, and MCT4) and aminoacylase 1 enzyme (ACY1) in HeLa cells as determined by RT-qPCR. Expression was normalised to P-actin, on a scale where P-actin expression equals 10,000 arbitrary units, (n = 2)
[0020] Fig. 2 is an image showing the pseudocoloured representation of TFEB-GFP localization in the nucleus before (left panel) and after treatment for 24 hours with N-acetyl-L-leucine (1 mM) (right panel).
[0021] Fig. 3 is a bar graph showing that N-acetyl-L-leucine enhances TFEB nuclear translocation.
[0022] Fig. 4A is a bar graph and line graph showing the concentration-dependent effects of N-acetyl-L-leucine on the degree of TFEB-GFP and nuclear localization in HeLa cells.
[0023] Fig. 4B is a bar graph and line graph showing the concentration-dependent effects of N-acetyl-L-leucine the percentage of HeLa cells displaying nuclear TFEB-GFP.
[0024] Fig. 5 is two line graphs showing the time course of activation of TFEB by N-acetyl-L-leucine. HeLa cells were continuously treated with N-acetyl-L-leucine (2 mM) and the migration of TFEB-GFP from cytoplasm to nucleus imaged by confocal microscopy.
[0025] Fig. 6 is two line graphs comparing the effect of N-acetyl-L-leucine (NALL) and L-leucine (LL) on TFEB-GFP nuclear translocation.
[0026] Fig. 7 is two line graphs comparing the effect of N-acetyl-L-leucine (NALL), N-acetyl-D-leucine (NADL), and N-acetyl-DL-lecuine (NALL+NADL) on TFEB-GFP nuclear translocation. Cells were incubated over night with N-acetyl-L-leucine, N-acetyl- D-leucine, or N-acetyl-DL-lecuine at the concentrations indicated and the colocalization of TFEB-GFP with nuclear staining or percentage of cells exhibiting nuclear TFEB-GFP were determined.
[0027] Fig. 8 is two line graphs and a bar graph showing N-acetyl-L-leucine reduces the degree of phosphorylation of mTOR serine 2448. HeLa cells were initially starved to reduce the phosphorylation state of mTOR and hence to reduce its activity. Cells were then stimulated with FCS to induce rephosphorylation as assessed by Western blot analysis using antibodies that specifically recognized the ser2448 phosphorylated form versus an antibody that recognizes the non-phosphorylated form. The degree of rephosphorylation of mTOR with FCS in the presence of known inhibitors of mTOR, rapamycin (100 pM) and torin (2 nM) was measured to confirm their inhibition of the enzyme complex. N-Acetyl-L-leucine (2 mM) was also found to reduce ser2448 phosphorylation substantially.
[0028] Fig. 9 is two bar graphs showing the TFEB activation in U18666A-treated HeLa cells. Treatment of HeLa cells with theNPCl inhibitor U18666A for 20 hr activated TFEB nuclear translocation to a similar extent to cells treated alone with N-acetyl-L-leucine (2 mM). Treatment of U18666A HeLa cells with N-acetyl-L-leucine (2 mM) reduced TFEB nuclear translocation.
[0029] Fig. 10 is a scheme showing the mechanisms of action of N-acetyl-L-leucine to enhance lysosomal and mitochondrial function.
[0030] Fig. 11 is a bar graph showing that N-acetyl-L-leucine (L) activates nuclear TFEB translocation in control (wild-type) cells and reduces nuclear TFEB in NpcT cells (a modelof Niemann-Pick disease Type C) and that N-acetyl-D-leucine (D) does not activate TFEB translocation in control cells and causes less nuclear TFEB reduction in Npcl^ cells.
[0031] Fig. 12 is a bar graph showing that N-acetyl-L-leucine (NALL) increases LAMP1 protein expression.
[0032] Fig. 13 is a bar graph showing that N-acetyl-L-leucine (NALL) treatment reduces lysosomal calcium in wild-type cells, but the D enantiomer (NADL) has no effect.
[0033] Fig. 14 is a bar graph showing that lysosomal calcium content is significantly reduced in MEC / ' 'cells compared to wild type (left hand bars) and in NPCl’ ’ cells, NALL normalises lysosomal calcium by increasing it (right hand bar) to levels similar to that seen in basal wild type cells (left hand bar).
[0034] Fig. 15A is a bar graph showing the nuclear localization TFEB-mScarlet in GM04912 cells either treated with vehicle (ctrl) or 2mM NALL.
[0035] Fig. 15B is a bar graph showing the nuclear localization TFEB-mScarlet in GM12932 cells either treated with vehicle (ctrl) or 2mM NALL.
[0036] Fig. 15C is a bar graph showing the nuclear localization TFEB-mScarlet in GM20161 cells either treated with vehicle (ctrl) or 2mM NALL.DETAILED DESCRIPTION
[0037] N-Acetyl-L-leucine is a pro-drug that increases intracellular L-leucine concentration. L-Leucine is an activator of mTOR and thus high cellular L-leucine concentrations would be expected to decrease TFEB translocation to the nucleus. Applicant has surprisingly discovered that treating cells with N-acetyl-L-leucine stimulates TFEB translocation to the nucleus thereby enhancing lysosomal biogenesis and autophagy. This effect would serve, for example, to ameliorate lysosomal storage disorders and promote autophagy. In other cells, however, where TFEB is excessively activated, e.g., in a diseased cell, N-acetyl-L-leucine reduces or normalizes TFEB levels in the nucleus of the cell.
[0038] Applicant has also surprisingly discovered that N-acetyl-L-leucine normalizes lysosomal calcium levels. Lysosomal calcium levels and calcium signaling are fundamental regulators of cellular processes including, but not limited to, intracellular trafficking, membrane fusion, autophagy, transcription factor regulation, inflammasome priming, and membrane excitability. Disrupted lysosomal calcium signaling is thereforethe cause of many neurodegenerative and neurological disorders, leading to impairment of cell function and ultimately to cell death. Without wishing to be bound by any particular theory or mechanism of action, regulation of the calcium signaling pathway by N-acetyl-L- leucine leads to lysosomal calcium homeostasis and an increase in cellular health in a subject.I. Transcription factor EB and Calcium Signaling
[0039] In one embodiment, the present disclosure provides a method of stimulating TFEB translocation from the cytoplasm of a cell to the nucleus of the cell, wherein the cell is contacted with an effective amount of N-acetyl leucine. The cell can be situated in vitro, ex vivo, or in vivo. In another embodiment, the cell is a neuronal cell. In another embodiment, the cell is a cancer cell. In another embodiment, the cell has an autophagy defect. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0040] In another embodiment, the present disclosure provides a method of stimulating TFEB translocation from the nucleus of a cell to the cytoplasm of the cell, wherein the cell is contacted with an effective amount of N-acetyl leucine. The cell can be situated in vitro, ex vivo, or in vivo. In another embodiment, the cell is a neuronal cell. In another embodiment, the cell is a cancer cell. In another embodiment, the cell has an autophagy defect. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0041] In another embodiment, the present disclosure provides a method of regulating TFEB activity in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0042] In another embodiment, the present disclosure provides a method of reducing or normalizing TFEB levels in the nucleus of the cell, e.g., as compared to baseline, in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L- leucine-2,3,3,4-d4. The baseline may be, for example, the nuclear TFEB level in a cell, e.g., a pathogenic or non-pathogenic cell, of a subject before initiating treatment for thedisease, disorder, syndrome, or condition. Alternatively, the baseline may be the nuclear TFEB level in a cell after a certain time period on treatment for the disease, disorder, syndrome, or condition. In some embodiments, administration of N-acetyl leucine as described herein improves the subject's assessment, e.g., nuclear TFEB level or activity, cytoplasmic TFEB level or activity, or other parameters, e.g., the intracellular clearance of pathogenic factors, enhanced autophagy, or improved lysosomal function, compared to a baseline by at least 2%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%. In one embodiment, assessment is improved by at least 60%, at least 70%, at least 80%, at least 90%, or 100%.
[0043] In another embodiment, the present disclosure provides a method of stimulating TFEB translocation from the cytoplasm of a cell to the nucleus of the cell in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject. In another embodiment, the N-acetyl leucine is N-acetyl- L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0044] In another embodiment, the present disclosure provides a method of stimulating TFEB translocation from the cytoplasm of a cell to the nucleus of the cell in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject. In another embodiment, the N-acetyl leucine is N-acetyl- L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0045] In another embodiment, the present disclosure provides a method of treating a disease, disorder, syndrome, or condition wherein regulation of TFEB provides a therapeutic benefit; e.g., a disease, disorder, syndrome, or condition characterized as having aberrant levels of TFEB; e.g., a disease, disorder, syndrome, or condition characterized as having mutations in the CTNS gene, which encodes cystinosin; a disease, disorder, syndrome, or condition characterized having impaired autophagic activity or autophagy defect; or a disease, disorder, syndrome, or condition characterized as having impaired lysosomal function. Foremost among these diseases are metabolic disorders, neurodegenerative disorders, neurodevelopmental disorders, and neurological disorders, cancer, and defective autophagy diseases.
[0046] In another embodiment, the present disclosure provides a method of modulating lysosomal calcium levels, e.g., restoring lysosomal calcium levels to baseline or a homeostatic state, in a cell of a subject in need thereof, the method comprisingadministering a therapeutically effective amount of N-acetyl leucine to the subject. The baseline may be, for example, the lysosomal calcium level in a cell, e.g., a pathogenic or non-pathogenic cell, of a subject before administering N-acetyl leucine. Alternatively, the baseline may be the lysosomal calcium level in a cell after a certain time period after administration of N-acetyl leucine. In some embodiments, administration of N-acetyl leucine as described herein normalizes or restores, the subject's assessment, e.g., lysosomal calcium level, cellular calcium signaling processes, compared to a baseline by, e.g., at least 2%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%. In one embodiment, assessment is improved by at least 60%, at least 70%, at least 80%, at least 90%, or 100%. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0047] In another embodiment, the present disclosure provides a method of treating a disease, disorder, syndrome, or condition wherein modulating, e.g., normalizing, the lysosomal calcium content in a cell of a subject provides a therapeutic benefit, e.g., a disease, disorder, syndrome, or condition characterized as having an aberrant level of lysosomal calcium in a cell of a subject. Foremost among these diseases are metabolic disorders, neurodegenerative disorders, neurodevelopmental disorders, and neurological disorders, cancer, and defective autophagy diseases.II. Metabolic Disorders
[0048] The term "metabolic disorders" refers to a group of conditions, diseases, disorders, or syndromes that affect the body's ability to process and use nutrients and energy from food. They occur when there are disruptions in the chemical reactions that convert nutrients into usable energy. Common metabolic disorders include, but are not limited to:
[0049] (i) carbohydrate metabolism disorders, e.g., diabetes and hypoglycemia
[0050] (ii) lipid metabolism disorders, e.g., obesity, high blood pressure, high cholesterol, and hyperglycemia;
[0051] (iii) protein metabolism disorders, e.g., phenylketonuria and maple syrup urine disease
[0052] (iv) lysosomal storage disorders, e.g., Gaucher disease, Niemann-Pick disease, Pompe disease, Tay-Sachs disease, Fabry disease, and mucopolysaccharidosis; and
[0053] (v) mitochondrial disorders, e.g., MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes), MERRF (Myoclonic Epilepsy with Ragged Red Fibers), Leigh syndrome, and Kearns-Sayre syndrome.
[0054] In another embodiment, the present disclosure provides a method of treating or preventing a metabolic disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject.
[0055] In another embodiment, the present disclosure provides a method of stimulating TFEB translocation from the cytoplasm of a cell to the nucleus of the cell in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a metabolic disorder, or a clinical manifestation thereof.
[0056] In another embodiment, the present disclosure provides a method of modulating the lysosomal calcium content in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a metabolic disorder, or a clinical manifestation thereof.
[0057] In another embodiment, the present disclosure provides a method of restoring normal calcium signaling in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a metabolic disorder, or a clinical manifestation thereof.
[0058] In another embodiment, the present disclosure provides a method of treating or preventing a metabolic disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine regulates the activity of TFEB, e.g., stimulates the translocation of TFEB from the cytoplasm of a cell to the nucleus of the cell.
[0059] In another embodiment, the present disclosure provides a method of treating or preventing a metabolic disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine modulates the lysosomal calcium content in a cell of the subject.
[0060] In another embodiment, the present disclosure provides a method of treating or preventing a metabolic disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine restores normal calcium signaling in a cell of the subject.
[0061] In another embodiment, the metabolic disorder is any one or more of the disorders listed in Table 1A.
[0062] In another embodiment, the clinical manifestation of the metabolic disorder is any one or more clinical manifestations listed in Table 1A.Table 1A
[0063] In another embodiment, N-acetyl leucine is administered the subject to treat a metabolic disorder of Table 1A. In another embodiment, the N-acetyl leucine is N-acetyl- L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0064] In another embodiment, N-acetyl leucine is administered the subject to treat a clinical manifestation(s) of the metabolic disorder of Table 1A. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N- acetyl-L-leucine-2,3,3,4-d4.
[0065] In another embodiment, N-acetyl leucine is administered the subject to prevent a metabolic disorder of Table 1A. In another embodiment, the N-acetyl leucine is N-acetyl- L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0066] In another embodiment, N-acetyl leucine is administered the subject to prevent a clinical manifestation(s) of the metabolic disorder of Table 1A. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N- acetyl-L-leucine-2,3,3,4-d4.
[0067] In another embodiment, the metabolic disorder is a lysosomal storage disease (LSD). In another embodiment, the LSD is sphingolipidoses, e.g., Farber disease and Krabbe disease; galactosialidosis; Fabry disease; Schindler disease; β-galactosidase / GM1 gangliosidosis; GM2 gangliosidosis, e.g., Sandhoff disease and Tay-Sachs disease; Gaucher disease, e.g., Gaucher Type I, Type II, and Type II; lysosomal acid lipase deficiency; Niemann-Pick disease, e.g., Types A and B; sulfatidosis; Hurler syndrome; Scheie syndrome; Hurler-Scheie syndrome; Hunter syndrome; Sanfilippo syndrome, e.g.,Types A-D; Morquio; Maroteaux-Lamy syndrome; Sly syndrome; hyaluronidase deficiency; Mucolipidosis, e.g., Types I-IV; Niemann-Pick disease Types C and D; neuronal ceroid lipofuscinoses, e.g., Types 1-10; Wolman disease; alpha-mannosidosis; beta-mannosidosis; aspartylglucosaminuria; fucosidosis; lysosomal transport diseases, e.g., cystinosis, pycnodysostosis, Salla disease / sialic acid storage disease, and infantile free sialic acid storage disease; glycogen storage diseases, e.g., Pompe disease and Danon disease; mucopolysaccharidosis; or cholesteryl ester storage disease. In another embodiment, the LSD is Niemann-Pick disease Type C.III. Neurodegenerative Disorders
[0068] The term "neurodegenerative disorder" refers to a group of conditions, diseases, disorders, or syndromes that cause the progressive degeneration and death of nerve cells (neurons) in the brain and spinal cord. This degeneration leads to a, for example, decline in cognitive function, motor skills, and other neurological abilities. Common neurodegenerative disorders include, but are not limited to, Alzheimer's disease, Parkinson's disease, prion disease, amyotrophic lateral sclerosis, motor neuron disease, Huntington's disease, spinal muscular atrophy, and spinocerebellar ataxia. See, e.g., Lamptey et al., Ini. J. Mol. Sci. 2022, 23, 1851. https: / / doi.org / 10.3390 / ijms23031851.
[0069] In another embodiment, the present disclosure provides a method of treating or preventing a neurodegenerative disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject. In some embodiments, the N-acetyl-L-leucine is administered to the subject for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 24 weeks.
[0070] In another embodiment, the present disclosure provides a method of stimulating TFEB translocation from the cytoplasm of a cell to the nucleus of the cell in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a neurodegenerative disorder, or a clinical manifestation thereof.
[0071] In another embodiment, the present disclosure provides a method of modulating the lysosomal calcium content in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a neurodegenerative disorder, or a clinical manifestation thereof.
[0072] In another embodiment, the present disclosure provides a method of restoring normal calcium signaling in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a neurodegenerative disorder, or a clinical manifestation thereof.
[0073] In another embodiment, the present disclosure provides a method of treating or preventing a neurodegenerative disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine regulates the activity of TFEB, e.g., stimulates the translocation of TFEB from the cytoplasm of a cell to the nucleus of the cell.
[0074] In another embodiment, the present disclosure provides a method of treating or preventing a neurodegenerative disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine modulates the lysosomal calcium content in a cell of the subject.
[0075] In another embodiment, the present disclosure provides a method of treating or preventing a neurodegenerative disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine restores normal calcium signaling in a cell of the subject.
[0076] In another embodiment, the neurodegenerative disorder is any one or more of the disorders listed in Table 2A.
[0077] In another embodiment, the neurodegenerative disorder is any one or more of the ataxia-related disorders listed in Table 2B.
[0078] In another embodiment, the clinical manifestation of the neurodegenerative disorder is any one or more of the clinical manifestations listed in Table 2A.
[0079] In another embodiment, the clinical manifestation of the neurodegenerative disorder is any one or more of the clinical manifestations listed in Table 2B.Table 2A - Neurodegenerative Disorders and SymptomsTable 2B - Ataxia-Related Neurodegenerative Disorders and Symptoms
[0080] In another embodiment, N-acetyl leucine is administered the subject to treat a neurodegenerative disorder of Table 2A and / or Table 2B. In another embodiment, the N- acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N- acetyl-L-leucine-2,3,3,4-d4.
[0081] In another embodiment, N-acetyl leucine is administered the subject to treat a clinical manifestation(s) of the neurodegenerative disorder of Table 2A and / or Table 2B. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0082] In another embodiment, N-acetyl leucine is administered the subject to prevent a neurodegenerative disorder of Table 2A and / or Table 2B. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N- acetyl-L-leucine-2,3,3,4-d4.
[0083] In another embodiment, N-acetyl leucine is administered the subject to prevent a clinical manifestation(s) of the neurodegenerative disorder of Table 2A and / or Table 2B. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.IV. Neurodevelopmental Disorders
[0084] The term "neurodevelopmental disorder" or " NDD" refers to a group of conditions, diseases, disorders, or syndromes characterized by abnormal neurodevelopment and / or basic biobehavioral processes, including attentional and perceptual processing, executive function, inhibitory control, e.g., sensory gating, social cognition, and communication and affiliative behaviors. NDDs usually onset during early stages of development which makes them most prevalent in toddlers, children, and adolescents. But some NDDs continue to persist into adulthood, or may go undiagnosed until one is an adult. Common NDDs include, but are not limited to, autism spectrum disorder (ASD) and attention- deficit / hyperactive disorder (ADHD). Many NDDs are rare genetic disorders that affect the brain and nervous system.
[0085] In another embodiment, the present disclosure provides a method of treating or preventing a neurodevelopmental disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject. In some embodiments, the N-acetyl-L-leucine is administered to the subject for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 24 weeks.
[0086] In another embodiment, the present disclosure provides a method of stimulating TFEB translocation from the cytoplasm of a cell to the nucleus of the cell in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a neurodevelopmental disorder, or a clinical manifestation thereof.
[0087] In another embodiment, the present disclosure provides a method of modulating the lysosomal calcium content in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a neurodevelopmental disorder, or a clinical manifestation thereof.
[0088] In another embodiment, the present disclosure provides a method of restoring normal calcium signaling in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a neurodevelopmental disorder, or a clinical manifestation thereof.
[0089] In another embodiment, the present disclosure provides a method of treating or preventing a neurodevelopmental disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine regulates the activity of TFEB, e.g., stimulates the translocation of TFEB from the cytoplasm of a cell to the nucleus of the cell.
[0090] In another embodiment, the present disclosure provides a method of treating or preventing a neurodevelopmental disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine modulates the lysosomal calcium content in a cell of the subject.
[0091] In another embodiment, the present disclosure provides a method of treating or preventing a neurodevelopmental disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine restores normal calcium signaling in a cell of the subject.
[0092] In another embodiment, the neurodegenerative disorder is any one or more of the disorders listed in Table 3A.
[0093] In another embodiment, the clinical manifestation, e.g., neurological symptoms, of the neurodegenerative disorder is any one or more of the clinical manifestations listed in Table 3A.
[0094] In another embodiment, the neurodegenerative disorder is any one or more of the C C 4-Related Neurodevelopmental Disorders listed in Table 3B. See Szymanowicz et al., Diseases 2024, 12, 90. doi.org / 10.3390 / diseasesl2050090.
[0095] In another embodiment, the clinical manifestation, e.g., neurological symptoms, of the (NCMd -Related Neurodevelopmental Disorders is any one or more of the clinical manifestations listed in Table 3B.
[0096] In another embodiment, the neurodegenerative disorder is any one or more of the CACNA1A -Related Neurodevel opmental Disorders listed in Table 3C.
[0097] In another embodiment, the clinical manifestation, e.g., neurological symptoms, of the CACNA1A -Related Neurodevelopmental Disorders is any one or more of the clinical manifestations listed in Table 3C.Table 3 A - Neurodevelopmental disorders and Neurological SymptomsTable 3B - CACNA -Related Neurodevel opmental DisordersTable 3C - C C -Related Neurodevel opmental DisordersBiological and Clinical Characteristics of C C -Related Neurodevelopmental Disorders
[0098] Episodic Ataxia Type 2 (EA2)
[0099] EA2 is an autosomal-dominant disorder caused by mutations (specifically expanded CAG repeats) in the gene CACNA1 A gene. It is classified as a Gain-of-Function variant of CACNA1A.
[0100] EA2 usually begins in early childhood, most often before the age of 20. Rarely, however, symptoms may first manifest in patients older than 50 years [Strupp et al. 2007], Such late onset may be related to certain mutations, such as, for example, multiple-base pair insertions in CACNA1A. Clinically, EA 2 is characterised by recurrent attacks of ataxia lasting for several hours to days, which are provoked by physical exertion, emotional stress, or alcohol. Several patients also have mild myasthenic symptoms (due to impaired neuromuscular transmission). Attacks may occur daily or over longer intervals, even years in some patients. Migraine headaches occur in approximately 50% of patients in more than half. Between spells, more than 90% of patients exhibit central ocular motor disturbances such as gaze-holding deficits, saccadic smooth pursuit, impaired visual suppression of the vestibulo-ocular reflex, especially down-beat nystagmus. Some of these patients develop subtle and slowly progressive limb ataxia and postural imbalance later in life. Cognitive impairment is also reported.
[0101] Familial Hemiplegic Migraine Type 1 (FHM1)
[0102] FHM1 is an autosomal -dominant disorder caused by mutations (specifically expanded CAG repeats) in the gene CACNA1 A gene. It is classified as a Loss-of-Function variant of CACNA1 A.
[0103] Hemiplegic attacks in familial hemiplegic migraine may begin as early as 5 to 7 years of age, with a mean age of onset of 12 years (range 1 to 51 years). FHM1 is defined by migraine with aura and motor weakness, with chronic progressive cerebellar ataxia occurring independently of migraine attacks. Seizures can occur rarely.
[0104] Spinocerebellar Ataxia Type 6 (SCA6)
[0105] SCA6 is an autosomal-dominant disorder caused by mutations (specifically expanded CAG repeats) in the gene CACNA1 A, which encodes the calcium voltage-gated subunit alphal A. It is classified as a Gain-of-Function variant of CACNA1 A.
[0106] The average age of onset of SCA6 is around 50 years of age. The disease progresses slowly and is regarded as having a relatively mild clinical phenotype and no effect on lifespan. Clinical symptoms include downbeat nystagmus, ataxia, double vision, pyramidal signs, deep sensory loss, and migraine. Magnetic resonance imaging (MRI) of SCA6 patients reveals atrophy in the cerebellum only. There are no reported effects on cognition. It is estimated that in North America SCA6 accounts for 15% of all autosomal- dominant cerebellar ataxias (ADAC).
[0107] Developmental and Epileptic Encephalopathy 42 (DEE42)
[0108] Developmental and epileptic encephalopathy-42 (DEE42) is an autosomal- dominant neurologic disorder. It is classified as a Loss-of-Function variant of CACNA1 A.
[0109] DEE42 is characterized by the onset of various types of seizures in the first hours or days of life, although rare patients may have onset in the first weeks of life. The seizures tend to be refractory and associated with EEG abnormalities, including multifocal spikes and generalized spike-wave complexes. Affected infants show global developmental delay with severely impaired intellectual development. Other features may include axial hypotonia, peripheral hypertonia with hyperreflexia, tremor, ataxia, and abnormal eye movements. DEE42 is an ultra-rare disease.
[0110] In another embodiment, N-acetyl leucine is administered the subject to treat a neurodegenerative disorder of Table 3A, Table 3B, and / or Table 3C. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0111] In another embodiment, N-acetyl leucine is administered the subject to treat a clinical manifestation(s) of the neurodegenerative disorder of Table 3 A, Table 3B, and / orTable 3C. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0112] In another embodiment, N-acetyl leucine is administered the subject to prevent the neurodegenerative disorder of Table 3A, Table 3B, and / or Table 3C. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0113] In another embodiment, N-acetyl leucine is administered the subject to prevent a clinical manifestation(s) of the neurodegenerative disorder of Table 3A, Table 3B, and / or Table 3C. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.V. Neurological disorders
[0114] The term "neurological disorder" refers to a group of conditions, diseases, disorders, or syndromes that disrupt the normal functioning of the brain, spinal cord, and / or nerves.
[0115] In another embodiment, the present disclosure provides a method of treating or preventing a neurological disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject. In some embodiments, the N-acetyl-L-leucine is administered to the subject for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 24 weeks.
[0116] In another embodiment, the present disclosure provides a method of stimulating TFEB translocation from the cytoplasm of a cell to the nucleus of the cell in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a neurological disorder, or a clinical manifestation thereof.
[0117] In another embodiment, the present disclosure provides a method of modulating the lysosomal calcium content in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a neurological disorder, or a clinical manifestation thereof.
[0118] In another embodiment, the present disclosure provides a method of restoring normal calcium signaling in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a neurological disorder, or a clinical manifestation thereof.
[0119] In another embodiment, the present disclosure provides a method of treating or preventing a neurological disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine regulates the activity of TFEB, e.g., stimulates the translocation of TFEB from the cytoplasm of a cell to the nucleus of the cell.
[0120] In another embodiment, the present disclosure provides a method of treating or preventing a neurological disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine modulates the lysosomal calcium content in a cell of the subject.
[0121] In another embodiment, the present disclosure provides a method of treating or preventing a neurological disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine restores normal calcium signaling in a cell of the subject.
[0122] In another embodiment, the neurological disorder is any one or more of the disorders listed in Table 4A.
[0123] In another embodiment, the clinical manifestation of the neurological disorder is any one or more of the clinical manifestations listed in Table 4A.Table 4A - Neurological disorders and Symptoms
[0124] In another embodiment, N-acetyl leucine is administered the subject to treat a neurological disorder of Table 4A. In another embodiment, the N-acetyl leucine is N- acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine- 2,3,3,4-d4.
[0125] In another embodiment, N-acetyl leucine is administered the subject to treat a clinical manifestation(s) of the neurological disorder of Table 4A. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0126] In another embodiment, N-acetyl leucine is administered the subject to prevent a neurological disorder of Table 4A. In another embodiment, the N-acetyl leucine is N- acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine- 2,3,3,4-d4.
[0127] In another embodiment, N-acetyl leucine is administered the subject to prevent a clinical manifestation(s) of the neurological disorder of Table 4A. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.VI. Cancer
[0128] The term "cancer" refers to a disease characterized by uncontrolled growth of abnormal cells.
[0129] In another embodiment, the present disclosure provides a method of treating or preventing cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject.
[0130] In another embodiment, the present disclosure provides a method of stimulating TFEB translocation from the cytoplasm of a cell to the nucleus of the cell in a subject in need thereof, the method comprising administering a therapeutically effective amount ofN-acetyl leucine to the subject, wherein the subject has cancer. In some embodiments, the N-acetyl-L-leucine is administered to the subject for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 24 weeks.
[0131] In another embodiment, the present disclosure provides a method of modulating the lysosomal calcium content in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has cancer.
[0132] In another embodiment, the present disclosure provides a method of restoring normal calcium signaling in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has cancer.
[0133] In another embodiment, the present disclosure provides a method of treating or preventing cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine regulates the activity of TFEB, e.g., stimulates the translocation of TFEB from the cytoplasm of a cell to the nucleus of the cell.
[0134] In another embodiment, the present disclosure provides a method of treating or preventing cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine modulates the lysosomal calcium content in a cell of the subject.
[0135] In another embodiment, the present disclosure provides a method of treating or preventing cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine restores normal calcium signaling in a cell of the subject
[0136] In another embodiment, the cancer is a solid tumor.
[0137] In another embodiment, the cancer is any one or more of the cancers listed in Table 5A.Table 5 A - Cancers
[0138] In another embodiment, the cancer is: (i) a bone tumor, e.g., adamantinoma, chondromas, chondroblastoma, chondrosarcoma, Ewing sarcoma, osteoblastoma, or osteosarcoma; (ii) a desmoid tumor; (iii) an endocrine tumor, e.g., adrenal tumors, carcinoid tumors, carney triad, multiple endocrine neoplasia (MEN), neuroendocrine tumors, paragangliomas / pheochromocytomas, thyroid carcinoma, or tumors of the pancreas; (iv) a germ cell tumor, e.g., ovarian tumors, teratoma, or testicular tumors; (v) a kidney (renal) tumor, e.g., malignant rhabdoid tumor or Wilms tumor; (vi) a liver tumor e.g., hepatoblastoma, hepatocellular carcinoma, or undifferentiated embryonal sarcoma of the liver (UESL); (vii) neuroblastoma; (vii) a rare tumor, e.g, adrenocortical carcinoma, melanoma, nasopharyngeal carcinoma, or odontogenic tumors; (ix) retinoblastoma; or (x) a soft tissue tumor, e.g., alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, dermatofibrosarcoma protuberans, epithelioid hemangioendothelioma, fibrosarcoma, hemangiopericytoma, juvenile nasopharyngeal angiofibroma (JNA), kaposiform hemangioendothelioma, leiomyosarcoma, liposarcoma, malignant fibrous histiocytoma, neurofibrosarcoma, rhabdomyosarcoma, schwannoma (neurilemoma), Spitz tumors, or synovial sarcoma.
[0139] In another embodiment, the cancer a hematological cancer. Exemplary hematological cancers include, but are not limited to, the cancers listed in Table 5B.Table 5B - Hematological Cancers
[0140] In another embodiment, N-acetyl leucine is administered the subject to treat a cancer of Table 5A and / or Table 5B. In another embodiment, the N-acetyl leucine is N- acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine- 2,3,3,4-d4.
[0141] In another embodiment, N-acetyl leucine is administered the subject to prevent a cancer of Table 5A and / or Table 5B. In another embodiment, the N-acetyl leucine is N- acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine- 2,3,3,4-d4.VII. Defective Autophagy Diseases
[0142] The terms "defective autophagy disease" or " DAD" refers to a disease characterized by aberrant autophagy and / or impaired lysosomal function that contributes to the pathogenesis of the disease. See, e.g., Jiang and Mizushima, Cell Research 24.69-19 (2014). Exemplary DADs beyond the ones listed in Sections II- VI include, but are not limited to, infectious disease, skeletal muscle disease, systemic lupus erythematosus, and kidney disease.
[0143] In another embodiment, the present disclosure provides a method of treating or preventing a DAD in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject. In some embodiments, the N-acetyl -L-leucine is administered to the subject for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 24 weeks.
[0144] In another embodiment, the present disclosure provides a method of stimulating TFEB translocation from the cytoplasm of a cell to the nucleus of the cell in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a DAD.
[0145] In another embodiment, the present disclosure provides a method of modulating the lysosomal calcium content in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a DAD, or a clinical manifestation thereof.
[0146] In another embodiment, the present disclosure provides a method of restoring normal calcium signaling in a cell of a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the subject has a DAD, or a clinical manifestation thereof.
[0147] In another embodiment, the present disclosure provides a method of treating or preventing a DAD in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine regulates the activity of TFEB, e.g., stimulates the translocation of TFEB from the cytoplasm of a cell to the nucleus of the cell.
[0148] In another embodiment, the present disclosure provides a method of treating or preventing a DAD disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine modulates the lysosomal calcium content in a cell of the subject.
[0149] In another embodiment, the present disclosure provides a method of treating or preventing a DAD disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine to the subject, wherein the administering of N-acetyl leucine restores normal calcium signaling in a cell of the subject.
[0150] In another embodiment, the DAD is an infectious disease.
[0151] In another embodiment, the DAD is a skeletal muscle disease.
[0152] In another embodiment, the DAD is systemic lupus erythematosus.
[0153] In another embodiment, the DAD is a kidney disease, e.g., cystinosis, acute kidney injury, and diabetic nephropathy.
[0154] In another embodiment, N-acetyl leucine is administered the subject to treat the DAD. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.
[0155] In another embodiment, N-acetyl leucine is administered the subject to prevent the DAD. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine. In another embodiment, the N-acetyl leucine is N-acetyl-L-leucine-2,3,3,4-d4.VIII. Definitions
[0156] The term "clinical manifestation" as used herein refer to the observable and measurable signs and symptoms that are associated with a disorder.
[0157] A "subject," as used herein, may be a vertebrate, mammal or domestic animal. Hence, compositions according to the disclosure may be used to treat any mammal, for example livestock, e.g. a horse, cow, sheep or pig, pets, e.g. a cat, dog, rabbit or guinea pig, a laboratory animal, e.g. a mouse or rat, or may be used in other veterinary applications. In one embodiment, the subject is a human. In some embodiments, the subject is a human subject who is 2 years old or less. In some embodiments, the subject is a human subject who is 2-10 years old. In some embodiments, the subject is a human subject who is 10-20 years old. In some embodiments, the subject is a human subject who is 20-30 years old. In some embodiments, the subject is a human subject who is 30-40 years old. In some embodiments, the subject is a human subject who is 40-50 years old. In some embodiments, the subject is a human subject who is 50 years old or more. " Subject" and "patient" are used interchangeably.
[0158] As used herein, the singular forms "a," "an," and "the" include plural reference.
[0159] As used herein, the term "about" should be generally understood to encompass ± 10% of a specified amount, frequency or value. Numerical quantities given herein are approximate unless stated otherwise, meaning that term "about" can be inferred when not expressly stated.
[0160] An "alteration" or "mutation" of a gene refers to a missense, nonsense, insertion, deletion, splice defect mutation, deletion, truncation, duplication, loss-of-function, and / or inversion of the gene.
[0161] The terms "administer," "administration," or "administering" as used herein refer to (1) providing, giving, dosing and / or prescribing by either a health practitioner or his authorized agent or under his direction, N-acetyl leucine; and (2) putting into, taking or consuming by the patient or person himself or herself, N-acetyl leucine.
[0162] The term " N-acetyl leucine" refers to N-acetyl-DL-leucine, N-acetyl-D-leucine, N- acetyl-L-leucine, N-acetyl-DL-leucine-2,3,3,4-d4, and / or N-acetyl-L-leucine-2,3,3,4-d4.N-acetyl-DL-leucine N-acetyl-D-leucine N-acetyl-L-leucine N-acetyl-DL-leucine-2,3,3,4-d4N-acetyl-L-leucine-2,3,3,4-d4Any reference to N-acetyl leucine includes pharmaceutically acceptable salts of the same, even if not expressly stated.
[0163] A "pharmaceutically acceptable salt" as referred to herein, is any salt preparation that is appropriate for use in a pharmaceutical application. Pharmaceutically acceptable salts include, but are not limited to, amine salts, such as N, N'-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chloro- benzyl-2-pyrrolidin-l'-ylmethylbenzimidazole, diethylamine and other alkylamines, piperazine, tri s(hydroxymethyl)aminom ethane and the like; alkali metal salts, such as lithium, potassium, sodium and the like; alkali earth metal salts, such as barium, calcium, magnesium and the like; transition metal salts, such as zinc, aluminum and the like; other metal salts, such as sodium hydrogen phosphate, di sodium phosphate and the like; mineral acids, such as hydrochlorides, sulfates and the like; and salts of organic acids, such as acetates, lactates, malates, tartrates, citrates, ascorbates, succinates, butyrates, valerates, fumarates and the like.
[0164] N-Acetyl leucine may be formulated and administered to a subject in accordance with known teachings in the art. For example, N-acetyl leucine may be formulated as a pharmaceutical composition. The pharmaceutical composition may comprise N-acetyl- DL-leucine and a pharmaceutically acceptable carrier, N-acetyl-L-leucine and a pharmaceutically acceptable carrier, or N-acetyl-D-leucine and a pharmaceutically acceptable carrier.
[0165] The pharmaceutical composition may take any of a number of different forms depending, in particular, on the manner in which it is to be used. Thus, for example, it may be in the form of a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micellar solution, transdermal patch, liposome suspension or any other suitable form that may be administered to a person or animal in need of treatment.
[0166] A "pharmaceutically acceptable carrier" as referred to herein, is any known compound or combination of known compounds, e.g., excipients, carriers, etc., that are known to those skilled in the art to be useful in formulating pharmaceutical compositions. It will be appreciated that the carrier of the pharmaceutical composition should be one which is tolerated by the subject to whom it is given.
[0167] In one embodiment, the pharmaceutically acceptable carrier may be a solid, and the composition may be in the form of a powder or tablet. A solid pharmaceutically acceptable carrier may include, but is not limited to, one or more substances which may also act as flavouring agents, buffers, lubricants, stabilisers, solubilisers, suspending agents, wetting agents, emulsifiers, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coatings, or tablet-disintegrating agents. The carrier may also be an encapsulating material. In powders, the carrier may be a finely divided solid that is in admixture with the finely divided active agents according to the disclosure. In tablets, the active agent may be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets may, for example, contain up to 99% of the active agents. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins. In another embodiment, the pharmaceutically acceptable carrier may be a gel and the composition may be in the form of a cream or the like.
[0168] The carrier may include, but is not limited to, one or more excipients or diluents.Examples of such excipients are gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like.
[0169] In another embodiment, the pharmaceutically acceptable carrier may be a liquid. In one embodiment, the pharmaceutical composition is in the form of a solution. Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs andpressurized compositions. N-acetyl leucine may be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier may contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, such as sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier may also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurised compositions may be a halogenated hydrocarbon or other pharmaceutically acceptable propellant.
[0170] Liquid pharmaceutical compositions, which are sterile solutions or suspensions, may be utilised by, for example, intramuscular, intrathecal, epidural, intraperitoneal, intravenous and subcutaneous injection. The active agent may be prepared as a sterile solid composition that may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium.
[0171] The compositions may be administered orally in the form of a sterile solution or suspension optionally containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like. The compositions may also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
[0172] Compositions may alternatively be administered by inhalation, e.g. intranasally.Compositions may also be formulated for topical use. For instance, creams or ointments may be applied to the skin.
[0173] N-acetyl leucine may be incorporated within a slow- or delayed-release device. Such devices may, for example, be inserted on or under the skin, and the medicament may be released over weeks or even months. Such devices may be advantageous when longterm treatment with N-acetyl leucine according to the present disclosure is required and which may require frequent administration, e.g. at least daily administration.
[0174] In one embodiment, the pharmaceutical composition is a solid oral dosage form, such as a tablet. In tablets, the active agent may be mixed with a vehicle, such as a pharmaceutically acceptable carrier, having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The tablets may contain up to 99% by weight of the N-acetyl leucine.
[0175] Pharmaceutical compositions in solid oral dosage form, such as tablets, may be prepared by any method known in the art of pharmacy. Pharmaceutical compositions are usually prepared by mixing the active agent with conventional pharmaceutically acceptable carriers.
[0176] A tablet may be formulated as is known in the art. Tanganil®, for example, includes wheat starch, pregelatinised maize (corn) starch, calcium carbonate and magnesium stearate as excipients. The same, or similar, excipients, for example, may be employed with the present disclosure.
[0177] The composition of each 700 mg Tanganil® tablet is as follows: 500 mg N-acetyl- DL-leucine, 88 mg wheat starch, 88 mg pregelatinised maize (corn) starch, 13 mg calcium carbonate and 11 mg magnesium stearate. The same tablets, for example, may be employed in the methods of the present disclosure.
[0178] In one embodiment, N-acetyl-L-leucine is formulated as granules for oral suspension in sachet. The granules for oral suspension may also comprise isomalt and / or hypromellose. Each sachet with 1000 mg of N-acetyl-L-leucine may be formulated, for example, to be suspended in 40 mL water.
[0179] As discussed above, N-acetyl leucine may be formulated and administered as a pharmaceutical composition taking any number of different forms. For example, N-acetyl leucine may be formulated as a pharmaceutical composition to facilitate its delivery across the blood-brain barrier. As a further example, N-acetyl leucine may be formulated as a pharmaceutical composition for bypassing the blood-brain barrier. Formulations that facilitate delivery across the blood-brain barrier or that are suitable for administration in amanner that bypasses the blood-brain barrier may be used to prepare and administer N-acetyl leucine.
[0180] In one embodiment, the pharmaceutical composition, e.g., a pharmaceutical composition comprising N-acetyl-L-leucine, or salt thereof, is formulated for nanodelivery, e.g., colloidal drug-carrier systems. Suitable examples include but are not limited to liposomes, nanoparticles (e.g., polymeric, lipid and inorganic nanoparticles), nanogels, dendrimers, micelles, nanoemulsions, polymersomes, exosomes, and quantum dots. See, e.g., Patel et al., " Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain," CNS Drugs 31:109-133 (2017); Kabanov et al., " New Technologies for Drug Delivery across the Blood Brain Barrier," Curr Pharm Des., 10(12): 1355-1363 (2004); Cheng et al., " Highly Stabilized Curcumin Nanoparticles Tested in an In Vitro Blood-Brain Barrier Model and in Alzheimer's Disease Tg2576 Mice," The AAPS Journal, vol. 15, no.2, pp. 324-336 (2013); Lahde et al. " Production of L-Leucine Nanoparticles under Various Conditions Using an Aerosol Flow Reactor Method," Journal of Nanomaterials, vol. 2008, article ID 680897 (2008).
[0181] In one embodiment, the pharmaceutical composition, e.g., a pharmaceutical composition comprising N-acetyl-L-leucine, or salt thereof, is formulated for direct delivery to the central nervous system (CNS), such as by injection or infusion. Formulations for and methods of direct delivery to the CNS are known in the art. See, e.g., U. S. Patent No. 9,283,181. Examples of such administration include but are not limited to intranasal, intraventricular, intrathecal, intracranial, and delivery via nasal mucosal grafting.
[0182] In one embodiment, the pharmaceutical composition is formulated for (and administered by) intranasal delivery. See, e.g., Hanson et al., " Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease," BMC Neurosci. 9(Suppl 3: S5 (2008). In one embodiment, the pharmaceutical composition is formulated for (and administered by) delivery via a nasal mucosal graft. In one embodiment, the pharmaceutical composition is formulated for (and administered by) intracerebroventricular injection or infusion. In another embodiment, the pharmaceutical composition is formulated for (and administered by) intrathecal intraci sternal injection or infusion. In one embodiment, the pharmaceutical composition is formulated for (and administered by) intrathecal lumbar injection or infusion.
[0183] Various techniques may be used including, without limitation, injection through a burrhole or cisternal or lumbar puncture or the like as known in the art. Various devices, whether internal (e.g., implanted) or external, may be used for delivery as known in the art, such as pumps, catheters, reservoirs, etc. In one embodiment, the administration interval is once every two weeks.
[0184] In one embodiment, the administration interval is once every month. In one embodiment, the administration interval is once every two months. In one embodiment, the administration interval is twice per month. In one embodiment, the administration interval is once every week. In one embodiment, the administration interval is twice or several times per week. In one embodiment, the administration interval is daily. In one embodiment, the administration is continuous, such as continuous infusion.
[0185] In one embodiment, the dose or amount equivalent of N-acetyl leucine may adjusted to account for either its direct delivery to the CNS or its delivery across the blood-brain barrier.
[0186] The terms "disease," "disorder," "syndrome," or "condition" denote disturbances and / or anomalies that are regarded as being pathological conditions or functions, and that can manifest themselves in the form of particular signs, symptoms, and / or malfunctions. N-acetyl-leucine regulates the activity of TFEB and thus can be used, for example, to treat or prevent diseases, disorders, syndromes, or conditions wherein regulation of TFEB provides a benefit.
[0187] The term "a disease, disorder, syndrome, or condition wherein regulation of TFEB provides a benefit" and the like pertains to a disease, disorder, syndrome, or condition in which TFEB is important or necessary, e.g., for the onset, progress, expression of that disease, disorder, syndrome, or condition, or a disease, disorder, syndrome or condition which is known to be responsive to TFEB regulation. One of ordinary skill in the art is readily able to determine whether a compound treats or prevents a disease mediated by TFEB for any particular cell type, for example, using in vitro, in vivo, and ex vivo assays that assess the activity of particular compounds.
[0188] A "subject in need thereof' as used herein may be any subject who has a disease, disorder, syndrome, or condition, e.g., a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, or clinical manifestation thereof, cancer, or a defective autophagy disease.
[0189] A "therapeutically effective amount" of N-acetyl leucine is any amount which, when administered to a subject, is the amount that is needed to produce the desired effect, which, for the present disclosure, can be therapeutic and / or prophylactic. The dose may be determined according to various parameters, such as the N-acetyl leucine used, e.g., N-acetyl-DL-leucine or N-acetyl-L-leucine; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient. For example, a daily dose may be from about 0.1 g to about 30 g, from about 1 g to about 15 g, or from about 3 g to about 10 g of N-acetyl leucine may be administered, e.g., as a tablet or an oral suspension.
[0190] As used herein, the terms "treat," "treating," or "treatment" refer to any indicia of success in arresting, reducing, or ameliorating a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, or a neurological disorder, and / or arresting, reducing, or ameliorating any one or more clinical manifestations, e.g., symptoms, of the disorder in a subject, including any objective or subjective parameter such as abatement; remission; diminishing, inhibiting, or eliminating one or more clinical manifestations; making the metabolic disorder, neurodegenerative disorder, neurodevelopmental disorder, or neurological disorder more tolerable to the subject; slowing in the worsening of the disorder; or improving the physical or mental well-being of the subject in need thereof.
[0191] The terms "treating" or "treatment" also encompasses, e.g., inducing inhibition, regression, rescue, or stasis of the disorder. For example, treatment of a subject in need of treatment for a neurodevelopmental disorder includes inhibiting or reducing a clinical manifestation of the neurodevelopmental disorder in the subject, inducing clinical response, inhibiting or reducing progression of a neurodevelopmental disorder, or inhibiting or reducing a complication of a neurodevelopmental disorder.
[0192] Arresting or ameliorating a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, or a neurological disorder, such as diminishing, inhibiting, or eliminating one or more clinical manifestations of the disorder can be based on objective and / or subjective parameters, including, e.g., the results of genetic testing, physical examination(s), neurological examination(s), and / or psychiatric evaluation(s). The success of treatment for the disorder may be measured or evaluated by, for example, comparing the severity of the disorder, or clinical manifestation thereof, before treatment with N-acetylleucine is initiated, with the severity of the disorder, or clinical manifestation thereof, following treatment with N-acetyl leucine. For example, the severity of a neurodevelopmental disorder, or clinical manifestation thereof, may be assessed using a scale, index, rating, or score. In one embodiment, the treatment described herein improves such an assessment from a value or degree characteristic of a symptomatic subject to a value or degree characteristic of a non-symptomatic subject. In one embodiment, the treatment described herein improves such an assessment compared to a baseline. The baseline may be, for example, the subject's condition, e.g., lysosomal calcium level, before initiating any treatment for the disorder, or clinical manifestation thereof, or before initiating treatment for the disorder, or clinical manifestation thereof, with N-acetyl leucine. Alternatively, the baseline may be, for example, the subject's condition after a certain time period on treatment for the disease. In one embodiment, treatment with N-acetyl leucine as described herein improves, e.g., normalizes, the subject's assessment, e.g., scale, index, rating, or score of objective, e.g., lysosomal calcium level, and / or subjective parameters, compared to a baseline by at least 1%, at least 2%, at least 3%, at least 4%, least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%. In one embodiment, assessment is improved by at least 60%, at least 70%, at least 80%, at least 90%, or 100%.
[0193] As used herein, the terms "prevent," "preventing," and "prevention" refer to a method of preventing the onset of a disease and / or its attendant clinical manifestations or barring a subject from acquiring a disease. As used herein, "prevent," "preventing," and "prevention" also include delaying the onset of a disease and / or its attendant clinical manifestations and reducing a subject's risk of acquiring a disease. The terms "prevent," "preventing" and "prevention" may include "prophylactic treatment," which refers to reducing the probability of redeveloping a disease, or of a recurrence of a previously- controlled disease, in a subject who does not have, but is at risk of or is susceptible to, redeveloping a disease or a recurrence of the disease.
[0194] As used herein, the terms "contacting," "contacted," and the like refers to the bringing together of TFEB an N-acetyl leucine in an in vitro system, an ex vivo system, or an in vivo system. For example, "contacting" TFEB with N-acetyl leucine includes the administration of N-acetyl leucine to a subject as well as, for example, introducing N-acetyl leucine into a sample comprising cells or tissue comprising TFEB.
[0195] The phrase "basal TFEB level" as used herein means the pre-intervention amount and / or localization state of TFEB in the relevant nucleated cell type before the cell is contacted with (or the subject is administered) N-acetyl-L-leucine or N-acetyl-L-leucine- 2,3,3,4-d4.
[0196] The phrase "localization state of TFEB" as used herein means where TFEB is located within the cell at a given time, i.e., whether TFEB is predominantly nuclear (in the nucleus) or predominantly cytoplasmic (in the cytoplasm). The localization state of TFEB can be described quantitatively as a nuclear-to-cytoplasmic (N: C) distribution / ratio.
[0197] The phrase " TFEB nuclear-to-cytoplasmic (N: C) ratio" as used herein means a quantitative measure of where TFEB is located inside a cell, specifically, how much TFEB is in the nucleus compared to the cytoplasm. Without wishing to be bound by any particular theory of mechanism of action, a higher N: C ratio indicates relatively more nuclear TFEB (greater nuclear localization), while a lower N: C ratio indicates relatively more cytoplasmic TFEB. In functional terms, because TFEB exerts its effects as a transcription factor in the nucleus, shifts in the N: C ratio are commonly used to indicate changes in TFEB activation status (nuclear translocation) and, by extension, lysosomal / autophagy gene program engagement.
[0198] The phrase "normalizes nuclear TFEB concentration" as used herein means shifting the nuclear TFEB concentration toward a homeostatic nuclear level when it is aberrantly high or aberrantly low in the relevant nucleated cell type.
[0199] The phrase "normalizes TFEB nuclear-to-cytoplasmic (N: C) ratio" as used herein means shifting the nuclear TFEB N: C ratio toward a homeostatic nuclear level when it is aberrantly high or aberrantly low in the relevant nucleated cell type.
[0200] The term "aberrant" as used herein in connection with nuclear TFEB concentration means abnormal relative to a homeostatic nuclear TFEB concentration.
[0201] The phrase "homeostatic nuclear TFEB concentration" as used herein means the normal, non-disease-associated nuclear amount of TFEB that a given relevant nucleated cell type maintains under typical physiologic conditions, i.e., the TFEB level consistent with balanced lysosomal / autophagy regulation.
[0202] The term "pathological TFEB" and the like as used herein means a TFEB concentration or localization state that is aberrant relative to a reference, e.g., homeostatic, level in the relevant nucleated cell type, e.g., an abnormally high or abnormally low nuclearTFEB concentration and / or abnormal nuclear-to-cytoplasmic localization, and that is associated with a disorder or a clinical manifestation thereof.
[0203] In one embodiment, N-acetyl leucine may be administered, for example, at a dose ranging from about 500 mg to about 30 g per day or ranging from about 500 mg to about 15 g per day, such as ranging from about 1 g to about 10 g per day, optionally by solid oral or liquid oral route, e.g., as an oral suspension. N-acetyl leucine, may be administered, for example, in a dose according to that of Tanganil®, which is prescribed to adults in a dose of 1.5 g to 2 g per day, 3-4 tablets in two doses, morning and evening.
[0204] If a single enantiomer, i.e., N-acetyl-D-leucine or N-acetyl-L-leucine, is administered the doses may be adjusted accordingly. For instance if N-acetyl-L-leucine is administered, the dose may range from about 250 mg to about 30 g per day, range from about 250 mg to about 15 g per day, range from about 1 mg to about 10 g per day, range from about 1 g to about 5 g per day, or range from about 2 g to about 4 g per day.
[0205] In one embodiment, the administered total daily dose ranges of N-acetyl leucine, e.g., N-acetyl-DL-leucine or N-acetyl-L-leucine, are from about 1 g to about 30 g per day, from about 1 g to about 15 g per day, from about 1 g to about 10 g per day, or from about 1.5 g to about 7 g per day, from 15.1 g to about 30 g per day, 16 g to about 30 g per day, 17 g to about 30 g per day, 18 g to about 30 g per day, 19 g to about 30 g per day, or 20 g to about 30 g per day. It may be from about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 g to about 15 g per day. It may be from about 2, 3, 4, 5, 6, 7, 8 or 9 g to about 10 g per day. It may be from 15.1, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 25, 27, 28, or 29 g to about 30 g per day. It may be more than about 1.5 g per day, but less than about 15, 14, 13, 12, 11, 10, 9, 8, 7, 6 or 5 g per day. In one embodiment, the dose ranges from about 4 g to about 6 g per day. In one embodiment, the dose ranges from about 4 g to about 5 g per day. In one embodiment, the dose is about 4.5 g per day. In one embodiment, the dose is about 5 g per day. In one embodiment, the dose is about 1 g per day, about 2 g per day, about 3 g per day, about 4 g per day, about 5 g per day, about 6 g per day, about 7 g per day, about 8 g per day, about 9 g per day, about 10 g per day, about 11 g per day, about 12 g per day, about 13 g per day, about 14 g per day, or about 15 g per day. In another embodiment, the dose is about 16 g per day, about 17 g per day, about 18 g per day, about 19 g per day, or about 20 g per day. In another embodiment, the dose is about 21 g per day, about 22 g per day, about 23 g per day, about 24 g per day, about 25 g per day, about 26 g per day, about27 g per day, about 28 g per day, about 29 g per day, or about 30 g per day. In one embodiment, these doses are administered in a solid oral dosage form, notably tablets, or as an oral suspension. In another embodiment, these doses are for N-acetyl leucine when in its racemic form. Doses for N-acetyl leucine when an enantiomeric excess is present may or may not be lower, for example, around 50% lower. The above recited dose-ranges when halved are thus also explicitly encompassed by the present disclosure.
[0206] In one embodiment, the total daily dose of N-acetyl leucine may be spread across multiple administrations, i.e., administration of N-acetyl leucine may occur two, three, four, or more times a day to achieve the total daily dose. As an example, the required number of tablets or amount of an oral suspension to provide the total daily dose of N-acetyl leucine may be split across two administrations (for example, in the morning and evening) or three administrations (for example, in the morning, noon, and evening). Each dose may be administered with or without food. For example, N-acetyl-L-leucine or N-acetyl-DL- leucine may be dosed by about 1 or about 2 hours before meals, such as at least about 20 minutes, at least about 30 minutes, at least about 40 minutes, or at least about 1 hour before meals, or may be dosed by about 1, about 2, or about 3 hours after meals, such as waiting at least about 20 minutes, at least about 30 minutes, at least about 1 hour, at least about 1.5 hours, at least about 2 hours, or at least about 2.5 hours after meals. For example, a total daily dose of 4.5 g N-acetyl-DL-leucine may be administered as three Tanganil® (or equivalent) tablets before, with, or after breakfast, three further tablets before, with, or after lunch and three further tablets before, with, or after dinner.
[0207] In another embodiment, the total daily dose of N-acetyl-L-leucine may be as determined according to a subject's body weight as provided in Table 6.Table 6
[0208] Treatment duration may be, for example, about seven days or more, about two weeks or more, about three weeks or more, about one month or more, about six weeks or more, about seven weeks or more, or about two months or more. In one embodiment, it is about three months or more, about four months or more, about five months or more or aboutsix months or more. The treatment duration may be about 1 year or more, about 2 years or more, about 4 years or more, about 5 years or more, or about 10 years or more. The treatment duration may be the life-time of the subject.
[0209] Any and all combinations of dosage form, dose amount, dosing schedule and treatment duration are envisaged and encompassed by the disclosure. In one embodiment, the dose of N-acetyl leucine is from about 4 g to about 15 g per day, taken across one, two, or three administrations per day, for a treatment duration of about two months or more. In another embodiment, the dose is more than 4 g but no more than 5 g per day, taken across one, two, or three administrations per day, for a treatment duration of about six months or more. The dosage form may be a solid oral dosage form, notably tablets. The dosage may also be in the form of an oral suspension.
[0210] N-acetyl leucine may be used as a monotherapy for treating or preventing a metabolic disorder, a neurodegenerative disorder, a neurodevel opmental disorder, or a neurological disorder, or a clinical manifestation thereof, in a subject. Alternatively, N-acetyl leucine may be used as an adjunct to, or in combination with, one or more therapeutic agents for treating or preventing a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, or a neurological disorder, or a clinical manifestation thereof, in a subject. The one or more therapeutic agents include, but are not limited to, growth hormone, risperidone, aripiprazole, trofinetide, atomoxetine, guanfacine, clonidine, viloxazine, haloperidol, pimozide, aripiprazole, onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, zolpidem, phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufmamide, clobazam, everolimus, cannabidiol, sapropterin hydrochloride, pegvaliase-pqpz, tasimelteon, ganaxolone, acetazolaminde, 4-aminopyridine, fampridine, flunarizine, and / or topiramate.
[0211] In some aspects, the additional therapeutic agent is growth hormone. In some aspects, the additional therapeutic agent is growth hormone and the subject has been diagnosed with Prader-Willi syndrome and / or Turner syndrome. In some aspects, the one or more additional therapeutic agents is risperidone and / or aripiprazole. In some aspects, the one or more additional therapeutic agents is risperidone and / or aripiprazole and the subject has been diagnosed with an autism spectrum disorder. In some aspects, theadditional therapeutic agent is trofinetide. In some aspects, the additional therapeutic agent is trofinetide and the subject has been diagnosed with Rett syndrome. In some aspects, the one or more additional therapeutic agents is atomoxetine, guanfacine, clonidine, and / or viloxazine. In some aspects, the one or more additional therapeutic agents is atomoxetine, guanfacine, clonidine, and / or viloxazine and the subject has been diagnosed with an attention deficit hyperactivity disorder (ADHD). In some aspects, the one or more additional therapeutic agents is haloperidol, pimozide, and / or aripiprazole. In some aspects, the one or more additional therapeutic agents is haloperidol, pimozide, and / or aripiprazole and the subject has been diagnosed with a Tic disorder. In some aspects, the one or more additional therapeutic agents is onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, and / or dantrolene. In some aspects, the one or more additional therapeutic agents is onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, and / or dantrolene and the subject has been diagnosed with spastic cerebral palsy. In some aspects, the one or more additional therapeutic agents is baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, and / or zolpidem. In some aspects, the one or more additional therapeutic agents is baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, and / or zolpidem and the subject has been diagnosed with dyskinetic cerebral palsy. In some aspects, the one or more additional therapeutic agents is onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, and / or zolpidem. In some aspects, the one or more additional therapeutic agents is onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, and / or zolpidem and the subject has been diagnosed with mixed cerebral palsy. In some aspects, the one or more additional therapeutic agents is phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufinamide, clobazam, everolimus, and / or cannabidiol. In some aspects, the one or more additional therapeutic agents is phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufinamide, clobazam, everolimus, and / or cannabidiol and the subject has been diagnosed with tuberous sclerosis. In some aspects, the one or more additional therapeutic agents issapropterin hydrochloride and / or pegvaliase-pqpz. In some aspects, the one or more additional therapeutic agents is sapropterin hydrochloride and / or pegvaliase-pqpz and the subject has been diagnosed with phenylketonuria (PKU). In some aspects, the additional therapeutic agent is tasimelteon. In some aspects, the additional therapeutic agent is tasimelteon and the subject has been diagnosed with Smith-Magenis syndrome. In some aspects, the additional therapeutic agent is ganaxolone. In some aspects, the additional therapeutic agent is ganaxolone and the subject has been diagnosed with CDKL5 deficiency disorder. In some aspects, the additional therapeutic agent is acetazolaminde, 4-aminopyridine, fampridine, flunarizine, and / or topiramate.
[0212] In another embodiment, the disclosure provides a kit comprising N-acetyl-DL- leucine, or a pharmaceutically acceptable salt thereof, and instructions for administering N- acetyl-DL-leucine, or a pharmaceutically acceptable to a subject having a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, or a clinical manifestation thereof, cancer, or a defective autophagy disease.
[0213] In another embodiment, the disclosure provides a kit comprising N-acetyl-L- leucine, or a pharmaceutically acceptable salt thereof, and instructions for administering N- acetyl-L-leucine, or a pharmaceutically acceptable salt thereof to a subject having a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, or a clinical manifestation thereof, cancer, or a defective autophagy disease.
[0214] In another embodiment, the disclosure provides a kit comprising N-acetyl-L- leucine-2,3,3,4-d4, or a pharmaceutically acceptable salt thereof, and instructions for administering N-acetyl-L-leucine-2,3,3,4-d4, or a pharmaceutically acceptable to a subject having a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, or a clinical manifestation thereof, cancer, or a defective autophagy disease.
[0215] In another embodiment, the disclosure provides a kit for carrying out the methods of the present disclosure, the kit comprising N-acetyl-L-leucine or N-acetyl-L-leucine- 2,3,3,4-d4 and a label with instructions for how to use the N-acetyl-L-leucine or N-acetyl- L-leucine-2,3,3,4-d4 to treat a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, or a clinical manifestation thereof, cancer, or a defective autophagy disease in a subject in need thereof.
[0216] In another embodiment, the label is approved by at least one regulatory health agency, e.g., the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), the China National Medical Products Administration (NMPA), or the Japanese Ministry of Health Labor and Welfare (MHLW).
[0217] All of the features described herein (including any accompanying claims, abstract and drawings), and / or all of the steps of any method so disclosed, may be combined with any of the above aspects in any combination, except combinations where at least some of such features and / or steps are mutually exclusive.IX. Particular Embodiments
[0218] The disclosure also provides the following method of treatment embodiments.
[0219] Embodiment 1. A method of:
[0220] (i) regulating transcription factor EB (TFEB) activity in a cell of a subject in need thereof;
[0221] (ii) modulating the lysosomal calcium level in a cell of a subject in need thereof;and / or
[0222] (iii) restoring normal calcium signaling, e.g., calcium homeostasis, in a cell of a subject in need thereof,
[0223] the method comprising administering a therapeutically effective amount of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4to the subject.
[0224] Embodiment 2. The method of Embodiment 1, wherein the N-acetyl-L- leucine orN-acetyl-L-leucine-2,3,3,4-d4 stimulates TFEB translocation from the cytoplasm of a cell to the nucleus of the cell compared to baseline.
[0225] Embodiment s. The method of Embodiment 1, wherein the N-acetyl-L- leucine or N-acetyl-L-leucine-2,3,3,4-d4 reduces or normalizes TFEB levels in the nucleus of the cell compared to baseline.
[0226] Embodiment 4. The method of Embodiment 1, wherein the N-acetyl-L- leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 modulates the lysosomal calcium level in a cell of a subject.
[0227] Embodiment s. The method of Embodiment 1, wherein the N-acetyl-L- leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 restores normal calcium signaling, e.g., calcium homeostasis, in a cell of a subject.
[0228] Embodiment 6. The method of any one of Embodiments 1-5, wherein the subject has a disorder, or a clinical manifestation thereof, wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease.
[0229] Embodiment 7. The method of Embodiment 6, wherein the N-acetyl-L- leucine is administered to treat the disorder in the subject.
[0230] Embodiment 8. The method of Embodiment 6, wherein N-acetyl-L-leucine is administered to treat the clinical manifestation of the disorder in the subject.
[0231] Embodiment 9. The method of Embodiment 6, wherein the N-acetyl-L- leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to prevent the disorder in the subject.
[0232] Embodiment 10. The method of Embodiment 6, wherein the N-acetyl-L- leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to prevent a clinical manifestation of the disorder in the subject.
[0233] Embodiment 11. The method of any one of Embodiments 6-10, wherein the disorder is a metabolic disorder.
[0234] Embodiment 12. The method of Embodiment 11, wherein the metabolic disorder is any one or more of the disorders listed in Table 1A.
[0235] Embodiment 13. The method of Embodiment 12, wherein the metabolic disorder is a lysosomal storage disease.
[0236] Embodiment 14. The method of Embodiment 13, wherein the lysosomal storage disease is Farber disease, Krabbe disease, galactosialidosis, Fabry disease; Schindler disease, β-galactosidase / GM1 gangliosidosis, Sandhoff disease, Tay-Sachs disease, Gaucher disease Type I, Gaucher disease Type II, Gaucher disease Type II, lysosomal acid lipase deficiency, Niemann-Pick disease Type A, Niemann-Pick disease Type B, sulfatidosis, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome Types A-D, Morquio, Maroteaux-Lamy syndrome, Sly syndrome, hyaluronidase deficiency,; Mucolipidosis, Types I-IV, Niemann-Pick disease Type C, Niemann-Pick disease Type D, neuronal ceroid lipofuscinoses Types 1-10, Wolman disease, alpha-mannosidosis, beta-mannosidosis, aspartylglucosaminuria; fucosidosis, cystinosis, pycnodysostosis, Salla disease / sialic acid storage disease, infantilefree sialic acid storage disease, Pompe disease, Danon disease, mucopolysaccharidosis, or cholesteryl ester storage disease.
[0237] Embodiment 15. The method of any one of Embodiments 6-10, wherein the disorder is a neurodegenerative disorder.
[0238] Embodiment 16. The method of Embodiment 15, wherein the neurodegenerative disorder is any one or more of the disorders listed in Table 2A and / or Table 2B.
[0239] Embodiment 17. The method of any one of Embodiments 6-10, wherein disorder is a neurodevelopmental disorder.
[0240] Embodiment 18. The method of Embodiment 17, wherein the neurodevelopmental disorder is any one or more of the disorders listed in Table 3A, Table 3B, and / or Table 3C.
[0241] Embodiment 19. The method of any one of Embodiments 6-10, wherein the disorder is a neurological disorder.
[0242] Embodiment 20. The method of Embodiment 19, wherein the neurological disorder is one or more of the disorders listed in Table 4A.
[0243] Embodiment 21. The method of any one of Embodiments 6-10, wherein the disorder is cancer.
[0244] Embodiment 22. The method of Embodiment 19, wherein cancer is one or more of the cancers listed in Table 5A and / or Table 5B.
[0245] Embodiment 23. The method of any one of Embodiments 6-10, wherein the disorder is a defective autophagy disease.
[0246] Embodiment 24. The method of Embodiment 23, wherein defective autophagy disease is infectious disease, skeletal muscle disease, systemic lupus erythematosus, or kidney disease.
[0247] Embodiment 25. The method of any one of Embodiments 1 -24, wherein a total dose of about 1 g to about 10 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject per day.
[0248] Embodiment 26. The method of Embodiment 25, wherein a total dose of about 1 g to about 8 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered to the subject per day.
[0249] Embodiment 27. The method of Embodiment 26, wherein a total dose of about 1 g to about 5 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered to the subject per day.
[0250] Embodiment 28. The method of any one of Embodiments 25-27, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered once a day, twice a day, or three times a day to the subject to achieve the total daily dose.
[0251] Embodiment 29. The method of any one of Embodiments 25-28, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject as a tablet or as an oral suspension.
[0252] Embodiment 30. The method of any one of Embodiments 1-29, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject in combination with one or more additional therapeutic agents.
[0253] Embodiment 31. The method of Embodiment 30, wherein the one or more additional therapeutic agents comprise growth hormone, risperidone, aripiprazole, trofinetide, atomoxetine, guanfacine, clonidine, viloxazine, haloperidol, pimozide, aripiprazole, onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, zolpidem, phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufmamide, clobazam, everolimus, cannabidiol, sapropterin hydrochloride, pegvaliase- pqpz, tasimelteon, ganaxolone, acetazolaminde, 4-aminopyridine, fampridine, flunarizine, and / or topiramate.
[0254] Embodiment 32. The method of any one of Embodiments 1-31 comprising administering N-acetyl-L-leucine to the subject.
[0255] Embodiment 33. The method of any one of Embodiments 1-31 comprising administering N-acetyl-L-leucine-2,3,3,4-d4 to the subject.
[0256] Embodiment 34. The method of any one of claims 1-33, wherein the N-acetyl- L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 24 weeks.
[0257] Embodiment 35. A method of treating or preventing a disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl leucine, e.g., N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4, to the subject, wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease.
[0258] Embodiment 36. The method of Embodiment 35, wherein the N-acetyl-L- leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered to treat the disorder in the subject.
[0259] Embodiment 37. The method of Embodiment 35, wherein N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to treat the clinical manifestation of the disorder in the subject.
[0260] Embodiment 38. The method of Embodiment 35, wherein the N-acetyl-L- leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to prevent the disorder in the subject.
[0261] Embodiment 39. The method of Embodiment 35, wherein the N-acetyl-L- leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to prevent a clinical manifestation of the disorder in the subject.
[0262] Embodiment 40. The method of any one of Embodiments 35-39, wherein the disorder is a metabolic disorder.
[0263] Embodiment 41. The method of Embodiment 40, wherein the metabolic disorder is any one or more of the disorders listed in Table 1A.
[0264] Embodiment 42. The method of Embodiment 41, wherein the metabolic disorder is a lysosomal storage disease.
[0265] Embodiment 43. The method of Embodiment 42, wherein the lysosomal storage disease is Farber disease, Krabbe disease, galactosialidosis, Fabry disease; Schindler disease, β-galactosidase / GM1 gangliosidosis, Sandhoff disease, Tay-Sachs disease, Gaucher disease Type I, Gaucher disease Type II, Gaucher disease Type II, lysosomal acid lipase deficiency, Niemann-Pick disease Type A, Niemann-Pick disease Type B, sulfatidosis, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome Types A-D, Morquio, Maroteaux-Lamy syndrome, Sly syndrome, hyaluronidase deficiency,; Mucolipidosis, Types I-IV, Niemann-Pick disease Type C, Niemann-Pick disease Type D, neuronal ceroid lipofuscinoses Types 1-10, Wolman disease, alpha-mannosidosis, beta-mannosidosis, aspartylglucosaminuria; fucosidosis, cystinosis, pycnodysostosis, Salla disease / sialic acid storage disease, infantilefree sialic acid storage disease, Pompe disease, Danon disease, mucopolysaccharidosis, or cholesteryl ester storage disease.
[0266] Embodiment 44. The method of any one of Embodiments 35-39, wherein the disorder is a neurodegenerative disorder.
[0267] Embodiment 45. The method of Embodiment 44, wherein the neurodegenerative disorder is any one or more of the disorders listed in Table 2A and / or Table 2B.
[0268] Embodiment 46. The method of any one of Embodiments 35-39, wherein disorder is a neurodevelopmental disorder.
[0269] Embodiment 47. The method of Embodiment 46, wherein the neurodevelopmental disorder is any one or more of the disorders listed in Table 3A, Table 3B, and / or Table 3C.
[0270] Embodiment 48. The method of any one of Embodiments 35-39, wherein the disorder is a neurological disorder.
[0271] Embodiment 49. The method of Embodiment 48, wherein the neurological disorder is one or more of the disorders listed in Table 4A.
[0272] Embodiment 50. The method of any one of Embodiments 35-39, wherein the disorder is cancer.
[0273] Embodiment 51. The method of Embodiment 50, wherein cancer is one or more of the cancers listed in Table 5A and / or Table 5B.
[0274] Embodiment 52. The method of any one of Embodiments 35-39, wherein the disorder is a defective autophagy disease.
[0275] Embodiment 53. The method of Embodiment 52, wherein defective autophagy disease is infectious disease, skeletal muscle disease, systemic lupus erythematosus, or kidney disease.
[0276] Embodiment 54. The method of any one of Embodiments 35-53, wherein a total dose of about 1 g to about 10 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4- d4 is administered to the subject per day.
[0277] Embodiment 55. The method of Embodiment 54, wherein a total dose of about 1 g to about 8 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3,3, 4-d4 is administered to the subject per day.
[0278] Embodiment 56. The method of Embodiment 55, wherein a total dose of about 1 g to about 5 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered to the subject per day.
[0279] Embodiment 57. The method of any one of Embodiments 54-56, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered once a day, twice a day, or three times a day to the subject to achieve the total daily dose.
[0280] Embodiment 58. The method of any one of Embodiments 54-57, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject as a tablet or as an oral suspension.
[0281] Embodiment 59. The method of any one of Embodiments 35-58, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject in combination with one or more additional therapeutic agents.
[0282] Embodiment 60. The method of Embodiment 59, wherein the one or more additional therapeutic agents comprise growth hormone, risperidone, aripiprazole, trofinetide, atomoxetine, guanfacine, clonidine, viloxazine, haloperidol, pimozide, aripiprazole, onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, zolpidem, phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufmamide, clobazam, everolimus, cannabidiol, sapropterin hydrochloride, pegvaliase- pqpz, tasimelteon, ganaxolone, acetazolaminde, 4-aminopyridine, fampridine, flunarizine, and / or topiramate.
[0283] Embodiment 61. The method of any one of Embodiments 35-60 comprising administering N-acetyl-L-leucine to the subject.
[0284] Embodiment 62. The method of any one of Embodiments 35-60 comprising administering N-acetyl-L-leucine-2,3,3,4-d4 to the subject.
[0285] Embodiment 63. The method of any one of claims 1 -62, wherein the N-acetyl- L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 24 weeks.
[0286] Embodiment 64. A kit for carrying out the method of any one of Embodiments 1-63, the kit comprising N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 andinstructions on how N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject.
[0287] Embodiment 1A. A method of treating or preventing a disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 to the subject, wherein the administering normalizes the nuclear TFEB concentration and / or the TFEB nuclear-to-cytoplasmic (N: C) ratio in a nucleated cell of the subject by:
[0288] (i) increasing the nuclear TFEB concentration and / or TFEB N: C ratio relative to an aberrantly low basal nuclear TFEB concentration and / or TFEB N: C ratio; or
[0289] (ii) decreasing the nuclear TFEB concentration and / or TFEB N: C ratio relative to an aberrantly high basal nuclear TFEB concentration and / or TFEB N: C ratio,
[0290] wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease.
[0291] Embodiment 2A. The method of Embodiment 1A, wherein the administering normalizes the nuclear TFEB concentration in a cell of the subject by increasing the nuclear TFEB concentration relative to the basal nuclear TFEB concentration.
[0292] Embodiment 3 A. The method of Embodiment 1A, wherein the administering normalizes the nuclear TFEB concentration in a cell of the subject by decreasing the nuclear concentration of TFEB relative to the basal nuclear TFEB concentration.
[0293] Embodiment 4A. The method of Embodiment 1A, wherein the administering normalizes the nuclear TFEB N: C ratio in a cell of the subject by increasing the nuclear TFEB N: C ratio relative to the basal nuclear TFEB N: C ratio.
[0294] Embodiment 5 A. The method of Embodiment Al, wherein the administering normalizes the nuclear TFEB N: C ratio in a cell of the subject by decreasing the nuclear TFEB N: C ratio relative to the basal nuclear TFEB N: C ratio.
[0295] Embodiment 6A. The method of Embodiment 2 A, wherein the nuclear TFEB concentration is increased relative to the basal nuclear TFEB concentration by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more; or the method of Embodiment 3 A, wherein the nuclear TFEB concentration is decreased relative to the basal nuclear TFEB concentration by about 2%,about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more.
[0296] Embodiment 7A. The method of Embodiment 4A, wherein the nuclear TFEB N: C ratio is increased relative to the basal nuclear TFEB N: C ratio by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more; or the method of Embodiment 5, wherein the nuclear TFEB N: C ratio is decreased relative to the basal nuclear TFEB N: C ratio by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more.
[0297] Embodiment 8 A. The method of any one of Embodiments 1 A-7A, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to treat the disorder in the subject.
[0298] Embodiment 9 A. The method of any one of Embodiments 1 A-7A, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to treat the clinical manifestation of the disorder in the subject.
[0299] Embodiment 10 A. The method of any one of Embodiments 1 A-7A, wherein the N-acetyl-L-leucine orN-acetyl-L-leucine-2,3,3,4-d4is administered to prevent the disorder in the subject.
[0300] Embodiment 11 A. The method of any one of Embodiments 1 A-7A, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to prevent a clinical manifestation of the disorder in the subject.
[0301] Embodiment 12A. The method of any one of Embodiments 1A-11A, wherein the disorder is a metabolic disorder.
[0302] Embodiment 13A. The method of Embodiment 12A, wherein the metabolic disorder is any one or more of the disorders listed in Table 1A.
[0303] Embodiment 14A. The method of Embodiment 13A, wherein the metabolic disorder is a lysosomal storage disease.
[0304] Embodiment 15 A. The method of Embodiment 14A, wherein the lysosomal storage disease is Farber disease, Krabbe disease, galactosialidosis, Fabry disease; Schindler disease, β-galactosidase / GM1 gangliosidosis, Sandhoff disease, Tay-Sachs disease, Gaucher disease Type I, Gaucher disease Type II, Gaucher disease Type II, lysosomal acid lipase deficiency, Niemann-Pick disease Type A, Niemann-Pick diseaseType B, sulfatidosis, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome Types A-D, Morquio, Maroteaux-Lamy syndrome, Sly syndrome, hyaluronidase deficiency,; Mucolipidosis, Types I-IV, Niemann-Pick disease Type C, Niemann-Pick disease Type D, neuronal ceroid lipofuscinoses Types 1-10, Wolman disease, alpha-mannosidosis, beta-mannosidosis, aspartylglucosaminuria; fucosidosis, cystinosis, pycnodysostosis, Salla disease / sialic acid storage disease, infantile free sialic acid storage disease, Pompe disease, Danon disease, mucopolysaccharidosis, or cholesteryl ester storage disease.
[0305] Embodiment 16A. The method of any one of Embodiments 1A-11A, wherein the disorder is a neurodegenerative disorder.
[0306] Embodiment 17 A. The method of Embodiment 16 A, wherein the neurodegenerative disorder is any one or more of the disorders listed in Table 2A.
[0307] Embodiment 18A. The method of any one of Embodiments 1A-11A, wherein disorder is a neurodevelopmental disorder.
[0308] Embodiment 19 A. The method of Embodiment 18 A, wherein the neurodevelopmental disorder is any one or more of the disorders listed in Table 3A, any one or more of the CACNA-related neurodevelopmental disorders listed in Table 3B, or any one or more of the CACNAlA-related neurodevelopmental disorders listed in Table 3C.
[0309] Embodiment 20A. The method of any one of Embodiments 1A-11A, wherein the disorder is a neurological disorder.
[0310] Embodiment 21 A. The method of Embodiment 20 A, wherein the neurological disorder is one or more of the disorders listed in Table 4A.
[0311] Embodiment 22A. The method of any one of Embodiments 1A-11A, wherein the disorder is cancer.
[0312] Embodiment 23 A. The method of Embodiment 22A, wherein cancer is one or more of the cancers listed in Table 5A and / or Table 5B.
[0313] Embodiment 24A. The method of any one of Embodiments 1A-11A, wherein the disorder is a defective autophagy disease.
[0314] Embodiment 25 A. The method of Embodiment 24A, wherein defective autophagy disease is infectious disease, skeletal muscle disease, systemic lupus erythematosus, or kidney disease.
[0315] Embodiment 26 A. The method of any one of Embodiments 1 A-25A, wherein a total dose of about 1 g to about 10 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3,3,4- d4 is administered to the subject per day.
[0316] Embodiment 27A. The method of Embodiment 26A, wherein a total dose of about 1 g to about 8 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 is administered to the subject per day.
[0317] Embodiment 28A. The method of Embodiment 27A, wherein a total dose of about 1 g to about 5 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 is administered to the subject per day.
[0318] Embodiment 29A. The method of any one of Embodiments 26A-28A, wherein N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 is administered once a day, twice a day, or three times a day to the subject to achieve the total daily dose.
[0319] Embodiment 30A. The method of any one of Embodiments 26A-29A, wherein N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 is administered to the subject as a tablet or as an oral suspension.
[0320] Embodiment 31 A. The method of any one of Embodiments 1A-30A, wherein N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 is administered to the subject in combination with one or more additional therapeutic agents.
[0321] Embodiment 32A. The method of Embodiment 31 A, wherein the one or more additional therapeutic agents comprise growth hormone, risperidone, aripiprazole, trofinetide, atomoxetine, guanfacine, clonidine, viloxazine, haloperidol, pimozide, aripiprazole, onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, zolpidem, phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufmamide, clobazam, everolimus, cannabidiol, sapropterin hydrochloride, pegvaliase- pqpz, tasimelteon, ganaxolone, acetazolaminde, 4-aminopyridine, fampridine, flunarizine, and / or topiramate.
[0322] Embodiment 33 A. The method of any one of Embodiments 1 A-32A comprising administering N-acetyl-L-leucine to the subject.
[0323] Embodiment 34A. The method of any one of Embodiments 1 A-32A comprising administering N-acetyl-L-leucine-2, 3, 3, 4-d4 to the subject.
[0324] Embodiment 35 A. The method of any one of Embodiments 1A-34A, wherein the nucleated cell is a neuron, glial cell, hepatocyte, myocyte, fibroblast, peripheral blood mononuclear cell (PBMC), or macrophage.
[0325] Embodiment 36 A. The method of any one of Embodiments 1A-35A, wherein the nuclear TFEB concentration is determined using an enzyme-linked immunosorbent assay (ELISA).
[0326] The disclosure also provides the following use-limited product embodiments.
[0327] Embodiment 1. N-Acetyl-L-leucine orN-acetyl-L-leucine-2,3,3,4-d4for use:
[0328] (i) in regulating transcription factor EB (TFEB) activity in a cell of a subject in need thereof;
[0329] (ii) modulating the lysosomal calcium level in a cell of a subject in need thereof;and / or
[0330] (iii) restoring normal calcium signaling, e.g., calcium homeostasis, in a cell of a subject.
[0331] Embodiment 2. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 1, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 stimulates TFEB translocation from the cytoplasm of a cell to the nucleus of the cell compared to baseline.
[0332] Embodiment 3. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 1, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 reduces or normalizes TFEB levels in the nucleus of the cell compared to baseline.
[0333] Embodiment 4. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 1, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 modulates the lysosomal calcium level in a cell of a subject.
[0334] Embodiment 5. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 1, restores normal calcium signaling, e.g., calcium homeostasis, in a cell of a subject.
[0335] Embodiment 6. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1-5, wherein the subject has a disorder, or a clinical manifestation thereof, wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease.
[0336] Embodiment 7. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 6, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to treat the disorder in the subject.
[0337] Embodiment 8. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 6, wherein N-acetyl-L-leucine orN-acetyl-L-leucine-2,3,3,4-d4 is to be administered to treat the clinical manifestation of the disorder in the subject.
[0338] Embodiment 9. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 6, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to prevent the disorder in the subject.
[0339] Embodiment 10. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 6 wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to prevent a clinical manifestation of the disorder in the subject.
[0340] Embodiment 11. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 6-10, wherein the disorder is a metabolic disorder.
[0341] Embodiment 12. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 11, wherein the metabolic disorder is any one or more of the disorders listed in Table 1A.
[0342] Embodiment 13. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 12, wherein the metabolic disorder is a lysosomal storage disease.
[0343] Embodiment 14. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 13, wherein the lysosomal storage disease is Farber disease, Krabbe disease, galactosialidosis, Fabry disease; Schindler disease, β-galactosidase / GM1 gangliosidosis, Sandhoff disease, Tay-Sachs disease, Gaucher disease Type I, Gaucher disease Type II, Gaucher disease Type II, lysosomal acid lipase deficiency, Niemann-Pick disease Type A, Niemann-Pick disease Type B, sulfatidosis, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome Types A-D, Morquio, Maroteaux-Lamy syndrome, Sly syndrome, hyaluronidase deficiency,; Mucolipidosis, Types I-IV, Niemann-Pick disease Type C, Niemann-Pick disease Type D, neuronal ceroid lipofuscinoses Types 1-10, Wolman disease, alpha-mannosidosis, beta- mannosidosis, aspartylglucosaminuria; fucosidosis, cystinosis, pycnodysostosis, Salla disease / sialic acid storage disease, infantile free sialic acid storage disease, Pompe disease, Danon disease, mucopolysaccharidosis, or cholesteryl ester storage disease.
[0344] Embodiment 15. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 6-10, wherein the disorder is a neurodegenerative disorder.
[0345] Embodiment 16. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 15, wherein the neurodegenerative disorder is any one or more of the disorders listed in Table 2A and / or Table 2B.
[0346] Embodiment 17. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 6-10, wherein disorder is a neurodevel opmental disorder.
[0347] Embodiment 18. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 17, wherein the neurodevelopmental disorder is any one or more of the disorders listed in Table 3A, Table 3B, and / or Table 3C.
[0348] Embodiment 19. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 6-10, wherein the disorder is a neurological disorder.
[0349] Embodiment 20. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 19, wherein the neurological disorder is one or more of the disorders listed in Table 4A.
[0350] Embodiment 21. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 6-10, wherein the disorder is cancer.
[0351] Embodiment 22. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 21, wherein cancer is one or more of the cancers listed in Table 5A and / or Table 5B.
[0352] Embodiment 23. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 6-10, wherein the disorder is a defective autophagy disease.
[0353] Embodiment 24. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 23, wherein defective autophagy disease is infectious disease, skeletal muscle disease, systemic lupus erythematosus, or kidney disease.
[0354] Embodiment 25. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1-24, wherein a total dose of about 1 g to about 10 g of N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject per day.
[0355] Embodiment 26. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 25, wherein a total dose of about 1 g to about 8 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered to the subject per day.
[0356] Embodiment 27. The N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 for use of Embodiment 26, wherein a total dose of about 1 g to about 5 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered to the subject per day.
[0357] Embodiment 28. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 25-27, wherein N-acetyl-L-leucine or N-acetyl-L-leucine- 2.3.3.4-d4is administered once a day, twice a day, or three times a day to the subject to achieve the total daily dose.
[0358] Embodiment 29. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 25-28, wherein N-acetyl-L-leucine or N-acetyl-L-leucine- 2.3.3.4-d4 is administered to the subject as a tablet or as an oral suspension.
[0359] Embodiment 30. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1-29, wherein N-acetyl-L-leucine or N-acetyl-L-leucine- 2,3,3,4-d4 is administered to the subject in combination with one or more additional therapeutic agents.
[0360] Embodiment 31. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 30, wherein the one or more additional therapeutic agents comprise growth hormone, risperidone, aripiprazole, trofinetide, atomoxetine, guanfacine, clonidine, viloxazine, haloperidol, pimozide, aripiprazole, onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, zolpidem, phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufmamide, clobazam, everolimus, cannabidiol, sapropterin hydrochloride, pegvaliase-pqpz, tasimelteon, ganaxolone, acetazolaminde, 4- aminopyridine, fampridine, flunarizine, and / or topiramate.
[0361] Embodiment 32. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1-31 comprising administering N-acetyl-L-leucine to the subject.
[0362] Embodiment 33. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1-31 comprising administering N-acetyl-L-leucine-2, 3, 3, 4- d4 to the subject.
[0363] Embodiment 34. The N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 for use of any one of Embodiments 1-33, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 24 weeks.
[0364] Embodiment 35. N-Acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use in treating or preventing a disorder, or a clinical manifestation thereof, in a subject in need thereof, wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease.
[0365] Embodiment 36. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 35, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to treat the disorder in the subject.
[0366] Embodiment 37. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 35, wherein N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to treat the clinical manifestation of the disorder in the subject.
[0367] Embodiment 38. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 35, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to prevent the disorder in the subject.
[0368] Embodiment 39. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 35, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to prevent a clinical manifestation of the disorder in the subject.
[0369] Embodiment 40. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 35-39, wherein the disorder is a metabolic disorder.
[0370] Embodiment 41. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 40, wherein the metabolic disorder is any one or more of the disorders listed in Table 1A.
[0371] Embodiment 42. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 41, wherein the metabolic disorder is a lysosomal storage disease.
[0372] Embodiment 43. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 42, wherein the lysosomal storage disease is Farber disease, Krabbe disease, galactosialidosis, Fabry disease; Schindler disease, β-galactosidase / GM1 gangliosidosis, Sandhoff disease, Tay-Sachs disease, Gaucher disease Type I, Gaucher disease Type II, Gaucher disease Type II, lysosomal acid lipase deficiency, Niemann-Pick disease Type A, Niemann-Pick disease Type B, sulfatidosis, Hurler syndrome, Scheiesyndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome Types A-D, Morquio, Maroteaux-Lamy syndrome, Sly syndrome, hyaluronidase deficiency,; Mucolipidosis, Types I-IV, Niemann-Pick disease Type C, Niemann-Pick disease Type D, neuronal ceroid lipofuscinoses Types 1-10, Wolman disease, alpha-mannosidosis, beta- mannosidosis, aspartylglucosaminuria; fucosidosis, cystinosis, pycnodysostosis, Salla disease / sialic acid storage disease, infantile free sialic acid storage disease, Pompe disease, Danon disease, mucopolysaccharidosis, or cholesteryl ester storage disease.
[0373] Embodiment 44. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 35-39, wherein the disorder is a neurodegenerative disorder.
[0374] Embodiment 45. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 44, wherein the neurodegenerative disorder is any one or more of the disorders listed in Table 2A and / or Table 2B.
[0375] Embodiment 46. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 35-39, wherein disorder is a neurodevelopmental disorder.
[0376] Embodiment 47. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 46, wherein the neurodevelopmental disorder is any one or more of the disorders listed in Table 3A, Table 3B, and / or Table 3C.
[0377] Embodiment 48. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 35-39, wherein the disorder is a neurological disorder.
[0378] Embodiment 49. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 48, wherein the neurological disorder is one or more of the disorders listed in Table 4A.
[0379] Embodiment 50. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 35-39, wherein the disorder is cancer.
[0380] Embodiment 51. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 50, wherein cancer is one or more of the cancers listed in Table 5A and / or Table 5B.
[0381] Embodiment 52. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 35-39, wherein the disorder is a defective autophagy disease.
[0382] Embodiment 53. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 52, wherein defective autophagy disease is infectious disease, skeletal muscle disease, systemic lupus erythematosus, or kidney disease.
[0383] Embodiment 54. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 35-53, wherein a total dose of about 1 g to about 10 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject per day.
[0384] Embodiment 55. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 54, wherein a total dose of about 1 g to about 8 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to the subject per day.
[0385] Embodiment 56. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 55, wherein a total dose of about 1 g to about 5 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to the subject per day.
[0386] Embodiment 57. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 54-56, wherein N-acetyl-L-leucine or N-acetyl-L-leucine- 2,3,3,4-d4 is to be administered once a day, twice a day, or three times a day to the subject to achieve the total daily dose.
[0387] Embodiment 58. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 54-57, wherein N-acetyl-L-leucine or N-acetyl-L-leucine- 2,3,3,4-d4 is administered to the subject as a tablet or as an oral suspension.
[0388] Embodiment 59. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 35-58, wherein N-acetyl-L-leucine or N-acetyl-L-leucine- 2,3,3,4-d4 is to be administered to the subject in combination with one or more additional therapeutic agents.
[0389] Embodiment 60. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 59, wherein the one or more additional therapeutic agents comprise growth hormone, risperidone, aripiprazole, trofinetide, atomoxetine, guanfacine, clonidine, viloxazine, haloperidol, pimozide, aripiprazole, onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, zolpidem, phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufmamide, clobazam, everolimus, cannabidiol,sapropterin hydrochloride, pegvaliase-pqpz, tasimelteon, ganaxolone, acetazolaminde, 4- aminopyridine, fampridine, flunarizine, and / or topiramate.
[0390] Embodiment 61. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 35-60 comprising administering N-acetyl-L-leucine to the subject.
[0391] Embodiment 62. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1-60 comprising administering N-acetyl-L-leucine-2, 3,3,4- d4 to the subject.
[0392] Embodiment 63. The N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 for use of any one of claims 1-62, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine- 2,3,3,4-d4 is to be administered to the subject for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 24 weeks.
[0393] Embodiment 1 A. N-Acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 for use treating or preventing a disorder, or a clinical manifestation thereof, in a subject in need thereof, wherein N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 is to be administered to normalize the nuclear TFEB concentration and / or the TFEB nuclear-to-cytoplasmic (N: C) ratio in a nucleated cell of the subject by:
[0394] (i) increasing the nuclear TFEB concentration and / or TFEB N: C ratio relative to an aberrantly low basal nuclear TFEB concentration and / or TFEB N: C ratio; or
[0395] (ii) decreasing the nuclear TFEB concentration and / or TFEB N: C ratio relative to an aberrantly high basal nuclear TFEB concentration and / or TFEB N: C ratio,
[0396] wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease.
[0397] Embodiment 2A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 for use of Embodiment 1A, wherein the administering normalizes the nuclear TFEB concentration in a cell of the subject by increasing the nuclear TFEB concentration relative to the basal nuclear TFEB concentration.
[0398] Embodiment 3 A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4-d4 for use of Embodiment 1A, wherein the administering normalizes the nuclear TFEB concentration in a cell of the subject by decreasing the nuclear concentration of TFEB relative to the basal nuclear TFEB concentration.
[0399] Embodiment 4A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 1A, wherein the administering normalizes the nuclear TFEB N:C ratio in a cell of the subject by increasing the nuclear TFEB N:C ratio relative to the basal nuclear TFEB N:C ratio.
[0400] Embodiment 5A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 1 A, wherein the administering normalizes the nuclear TFEB N: C ratio in a cell of the subj ect by decreasing the nuclear TFEB N: C ratio relative to the basal nuclear TFEB N: C ratio.
[0401] Embodiment 6A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 2A, wherein the nuclear TFEB concentration is increased relative to the basal nuclear TFEB concentration by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more; or the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 3A, wherein the nuclear TFEB concentration is decreased relative to the basal nuclear TFEB concentration by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more.
[0402] Embodiment 7A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 4A, wherein the nuclear TFEB N: C ratio is increased relative to the basal nuclear TFEB N: C ratio by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more; or the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 5A, wherein the nuclear TFEB N: C ratio is decreased relative to the basal nuclear TFEB N: C ratio by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more.
[0403] Embodiment 8A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1 A-7A, wherein the N-acetyl-L-leucine or N-acetyl-L- leucine-2,3,3,4-d4is administered to treat the disorder in the subject.
[0404] Embodiment 9A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1A-7A, wherein N-acetyl-L-leucine orN-acetyl-L-leucine- 2,3,3,4-d4 is to be administered to treat the clinical manifestation of the disorder in the subject.
[0405] Embodiment 10A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1 A-7A, wherein the N-acetyl-L-leucine or N-acetyl-L- leucine-2,3,3,4-d4is to be administered to prevent the disorder in the subject.
[0406] Embodiment 11 A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1 A-7A, wherein the N-acetyl-L-leucine or N-acetyl-L- leucine-2,3,3,4-d4 is to be administered to prevent a clinical manifestation of the disorder in the subject.
[0407] Embodiment 12A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1 A-l 1 A, wherein the disorder is a metabolic disorder.
[0408] Embodiment 13A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 12A, wherein the metabolic disorder is any one or more of the disorders listed in Table 1A.
[0409] Embodiment 14A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 13 A, wherein the metabolic disorder is a lysosomal storage disease.
[0410] Embodiment 15 A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 14A, wherein the lysosomal storage disease is Farber disease, Krabbe disease, galactosialidosis, Fabry disease; Schindler disease, β-galactosidase / GM1 gangliosidosis, Sandhoff disease, Tay-Sachs disease, Gaucher disease Type I, Gaucher disease Type II, Gaucher disease Type II, lysosomal acid lipase deficiency, Niemann-Pick disease Type A, Niemann-Pick disease Type B, sulfatidosis, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome Types A-D, Morquio, Maroteaux-Lamy syndrome, Sly syndrome, hyaluronidase deficiency,; Mucolipidosis, Types I-IV, Niemann-Pick disease Type C, Niemann-Pick disease Type D, neuronal ceroid lipofuscinoses Types 1-10, Wolman disease, alpha-mannosidosis, beta- mannosidosis, aspartylglucosaminuria; fucosidosis, cystinosis, pycnodysostosis, Salla disease / sialic acid storage disease, infantile free sialic acid storage disease, Pompe disease, Danon disease, mucopolysaccharidosis, or cholesteryl ester storage disease.
[0411] Embodiment 16A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1A-11A, wherein the disorder is a neurodegenerative disorder.
[0412] Embodiment 17A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 16A, wherein the neurodegenerative disorder is any one or more of the disorders listed in Table 2A.
[0413] Embodiment 18A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1A-11A, wherein disorder is a neurodevelopmental disorder.
[0414] Embodiment 19A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 18 A, wherein the neurodevelopmental disorder is any one or more of the disorders listed in Table 3A, any one or more of the CACNA-related neurodevelopmental disorders listed in Table 3B, or any one or more of the CACNA1 A- related neurodevelopmental disorders listed in Table 3C.
[0415] Embodiment 20A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1 A-l 1 A, wherein the disorder is a neurological disorder.
[0416] Embodiment 21 A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 20A, wherein the neurological disorder is one or more of the disorders listed in Table 4A.
[0417] Embodiment 22A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1 A-l 1 A, wherein the disorder is cancer.
[0418] Embodiment 23 A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 22A, wherein cancer is one or more of the cancers listed in Table 5 A and / or Table 5B.
[0419] Embodiment 24A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1A-11A, wherein the disorder is a defective autophagy disease.
[0420] Embodiment 25 A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 of Embodiment 24A, wherein defective autophagy disease is infectious disease, skeletal muscle disease, systemic lupus erythematosus, or kidney disease.
[0421] Embodiment 26A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1 A-25A, wherein a total dose of about 1 g to about 10 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject per day.
[0422] Embodiment 27 A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 26A, wherein a total dose of about 1 g to about 8 g of N-acetyl-L- leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to the subject per day.
[0423] Embodiment 28A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 27A, wherein a total dose of about 1 g to about 5 g of N-acetyl-L- leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to the subject per day.
[0424] Embodiment 29A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 26A-28A, wherein N-acetyl-L-leucine or N-acetyl-L- leucine-2,3,3,4-d4is to be administered once a day, twice a day, or three times a day to the subject to achieve the total daily dose.
[0425] Embodiment 30A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 26A-29A, wherein N-acetyl-L-leucine or N-acetyl-L- leucine-2,3,3,4-d4 is to be administered to the subject as a tablet or as an oral suspension.
[0426] Embodiment 31 A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1A-30A, wherein N-acetyl-L-leucine or N-acetyl-L- leucine-2,3,3,4-d4 is to be administered to the subject in combination with one or more additional therapeutic agents.
[0427] Embodiment 32A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of Embodiment 31 A, wherein the one or more additional therapeutic agents comprise growth hormone, risperidone, aripiprazole, trofinetide, atomoxetine, guanfacine, clonidine, viloxazine, haloperidol, pimozide, aripiprazole, onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, zolpidem, phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufmamide, clobazam, everolimus, cannabidiol, sapropterin hydrochloride, pegvaliase-pqpz, tasimelteon, ganaxolone, acetazolaminde, 4- aminopyridine, fampridine, flunarizine, and / or topiramate.
[0428] Embodiment 33 A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1 A-32A, wherein N-acetyl-L-leucine is to be administered to the subject.
[0429] Embodiment 34A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1A-32A, wherein N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject.
[0430] Embodiment 35A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1 A-34A, wherein the nucleated cell is a neuron, glial cell, hepatocyte, myocyte, fibroblast, peripheral blood mononuclear cell (PBMC), or macrophage.
[0431] Embodiment 36A. The N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 for use of any one of Embodiments 1A-35A, wherein the nuclear TFEB concentration is determined using an enzyme-linked immunosorbent assay (ELISA).
[0432] The disclosure also provides the following use-limited process embodiments.
[0433] Embodiment 1. Use of N-Acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 in the manufacture of a medicament for:
[0434] (i) regulating transcription factor EB (TFEB) activity in a cell of a subject in need thereof;
[0435] (ii) modulating the lysosomal calcium level in a cell of a subject in need thereof;and / or
[0436] (iii) restoring normal calcium signaling, e.g., calcium homeostasis, in a cell of a subject.
[0437] Embodiment 2. The use of Embodiment 1, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 stimulates TFEB translocation from the cytoplasm of a cell to the nucleus of the cell compared to baseline.
[0438] Embodiment s. The use of Embodiment 1, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 reduces or normalizes TFEB levels in the nucleus of the cell compared to baseline.
[0439] Embodiment 4. The use of Embodiment 1, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 modulates the lysosomal calcium level in a cell of a subject.
[0440] Embodiment s. The use of Embodiment 1, restores normal calcium signaling, e.g., calcium homeostasis, in a cell of a subject
[0441] Embodiment 6. The use of any one of Embodiments 1-6, wherein the subject has a disorder, or a clinical manifestation thereof, wherein the disorder is a metabolicdisorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease.
[0442] Embodiment 7. The use of Embodiment 6, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to treat the disorder in the subject.
[0443] Embodiment 8. The use of Embodiment 6, wherein N-acetyl-L-leucine or N- acetyl-L-leucine-2,3,3,4-d4 is to be administered to treat the clinical manifestation of the disorder in the subject.
[0444] Embodiment 9. The use of Embodiment 6, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to prevent the disorder in the subject.
[0445] Embodiment 10. The use of Embodiment 6, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to prevent a clinical manifestation of the disorder in the subject.
[0446] Embodiment 11. The use of any one of Embodiments 6-10, wherein the disorder is a metabolic disorder.
[0447] Embodiment 12. The use of Embodiment 11, wherein the metabolic disorder is any one or more of the disorders listed in Table 1A.
[0448] Embodiment 13. The use of Embodiment 12, wherein the metabolic disorder is a lysosomal storage disease.
[0449] Embodiment 14. The use of Embodiment 13, wherein the lysosomal storage disease is Farber disease, Krabbe disease, galactosialidosis, Fabry disease; Schindler disease, β-galactosidase / GM1 gangliosidosis, Sandhoff disease, Tay-Sachs disease, Gaucher disease Type I, Gaucher disease Type II, Gaucher disease Type II, lysosomal acid lipase deficiency, Niemann-Pick disease Type A, Niemann-Pick disease Type B, sulfatidosis, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome Types A-D, Morquio, Maroteaux-Lamy syndrome, Sly syndrome, hyaluronidase deficiency,; Mucolipidosis, Types I-IV, Niemann-Pick disease Type C, Niemann-Pick disease Type D, neuronal ceroid lipofuscinoses Types 1-10, Wolman disease, alpha-mannosidosis, beta-mannosidosis, aspartylglucosaminuria; fucosidosis, cystinosis, pycnodysostosis, Salla disease / sialic acid storage disease, infantile free sialic acid storage disease, Pompe disease, Danon disease, mucopolysaccharidosis, or cholesteryl ester storage disease.
[0450] Embodiment 15. The use of any one of Embodiments 6-10, wherein the disorder is a neurodegenerative disorder.
[0451] Embodiment 16. The use of Embodiment 15, wherein the neurodegenerative disorder is any one or more of the disorders listed in Table 2A and / or Table 2B.
[0452] Embodiment 17. The use of any one of Embodiments 6-10, wherein disorder is a neurodevelopmental disorder.
[0453] Embodiment 18. The use of Embodiment 17, wherein the neurodevelopmental disorder is any one or more of the disorders listed in Table 3A, Table 3B, and / or Table 3C.
[0454] Embodiment 19. The use of any one of Embodiments 6-10, wherein the disorder is a neurological disorder.
[0455] Embodiment 20. The use of Embodiment 19, wherein the neurological disorder is one or more of the disorders listed in Table 4A.
[0456] Embodiment 21. The use of any one of Embodiments 4-6, wherein the disorder is cancer.
[0457] Embodiment 22. The use of Embodiment 19, wherein cancer is one or more of the cancers listed in Table 5A and / or Table 5B.
[0458] Embodiment 23. The use of any one of Embodiments 6-10, wherein the disorder is a defective autophagy disease.
[0459] Embodiment 24. The use of Embodiment 23, wherein defective autophagy disease is infectious disease, skeletal muscle disease, systemic lupus erythematosus, or kidney disease.
[0460] Embodiment 25. The use of any one of Embodiments 1-24, wherein a total dose of about 1 g to about 10 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject per day.
[0461] Embodiment 26. The use of Embodiment 25, wherein a total dose of about 1 g to about 8 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered to the subject per day.
[0462] Embodiment 27. The use of Embodiment 26, wherein a total dose of about 1 g to about 5 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered to the subject per day.
[0463] Embodiment 28. The use of any one of Embodiments 25-27, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered once a day, twice a day, or three times a day to the subject to achieve the total daily dose.
[0464] Embodiment 29. The use of any one of Embodiments 25-28, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject as a tablet or as an oral suspension.
[0465] Embodiment 30. The use of any one of Embodiments 1-29, wherein N-acetyl- L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject in combination with one or more additional therapeutic agents.
[0466] Embodiment 31. The use of Embodiment 30, wherein the one or more additional therapeutic agents comprise growth hormone, risperidone, aripiprazole, trofinetide, atomoxetine, guanfacine, clonidine, viloxazine, haloperidol, pimozide, aripiprazole, onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, zolpidem, phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufmamide, clobazam, everolimus, cannabidiol, sapropterin hydrochloride, pegvaliase- pqpz, tasimelteon, ganaxolone, acetazolaminde, 4-aminopyridine, fampridine, flunarizine, and / or topiramate.
[0467] Embodiment 32. The use of any one of Embodiments 1-31 comprising administering N-acetyl-L-leucine to the subject.
[0468] Embodiment 33. The use of any one of Embodiments 1-31 comprising administering N-acetyl-L-leucine-2,3,3,4-d4 to the subject.
[0469] Embodiment 34. The use of any one of Embodiments 1-33, wherein the N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 24 weeks.
[0470] Embodiment 35. Use of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 in the manufacture of a medicament for treating or preventing a disorder, or a clinical manifestation thereof, in a subject in need thereof, wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease.
[0471] Embodiment 36. The use of Embodiment 35, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to treat the disorder in the subject.
[0472] Embodiment 37. The use of Embodiment 35, wherein N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to treat the clinical manifestation of the disorder in the subject.
[0473] Embodiment 38. The use of Embodiment 35, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to prevent the disorder in the subject.
[0474] Embodiment 39. The use of Embodiment 35, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to prevent a clinical manifestation of the disorder in the subject.
[0475] Embodiment 40. The use of any one of Embodiments 35-39, wherein the disorder is a metabolic disorder.
[0476] Embodiment 41. The use of Embodiment 40, wherein the metabolic disorder is any one or more of the disorders listed in Table 1A.
[0477] Embodiment 42. The use of Embodiment 41, wherein the metabolic disorder is a lysosomal storage disease.
[0478] Embodiment 43. The use of Embodiment 42, wherein the lysosomal storage disease is Farber disease, Krabbe disease, galactosialidosis, Fabry disease; Schindler disease, β-galactosidase / GM1 gangliosidosis, Sandhoff disease, Tay-Sachs disease, Gaucher disease Type I, Gaucher disease Type II, Gaucher disease Type II, lysosomal acid lipase deficiency, Niemann-Pick disease Type A, Niemann-Pick disease Type B, sulfatidosis, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome Types A-D, Morquio, Maroteaux-Lamy syndrome, Sly syndrome, hyaluronidase deficiency,; Mucolipidosis, Types I-IV, Niemann-Pick disease Type C, Niemann-Pick disease Type D, neuronal ceroid lipofuscinoses Types 1-10, Wolman disease, alpha-mannosidosis, beta-mannosidosis, aspartylglucosaminuria; fucosidosis, cystinosis, pycnodysostosis, Salla disease / sialic acid storage disease, infantile free sialic acid storage disease, Pompe disease, Danon disease, mucopolysaccharidosis, or cholesteryl ester storage disease.
[0479] Embodiment 44. The use of any one of Embodiments 35-39, wherein the disorder is a neurodegenerative disorder.
[0480] Embodiment 45. The use of Embodiment 44, wherein the neurodegenerative disorder is any one or more of the disorders listed in Table 2A and / or Table 2B.
[0481] Embodiment 46. The use of any one of Embodiments 35-39, wherein disorder is a neurodevelopmental disorder.
[0482] Embodiment 47. The use of Embodiment 46, wherein the neurodevelopmental disorder is any one or more of the disorders listed in Table 3A, Table 3B, and / or Table 3C.
[0483] Embodiment 48. The use of any one of Embodiments 35-39, wherein the disorder is a neurological disorder.
[0484] Embodiment 49. The use of Embodiment 48, wherein the neurological disorder is one or more of the disorders listed in Table 4A.
[0485] Embodiment 50. The use of any one of Embodiments 35-39, wherein the disorder is cancer.
[0486] Embodiment 51. The use of Embodiment 50, wherein cancer is one or more of the cancers listed in Table 5A and / or Table 5B.
[0487] Embodiment 52. The use of any one of Embodiments 35-39, wherein the disorder is a defective autophagy disease.
[0488] Embodiment 53. The use of Embodiment 52, wherein defective autophagy disease is infectious disease, skeletal muscle disease, systemic lupus erythematosus, or kidney disease.
[0489] Embodiment 54. The use of any one of Embodiments 35-53, wherein a total dose of about 1 g to about 10 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject per day.
[0490] Embodiment 55. The use of Embodiment 54, wherein a total dose of about 1 g to about 8 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to the subject per day.
[0491] Embodiment 56. The use of Embodiment 55, wherein a total dose of about 1 g to about 5 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered to the subject per day.
[0492] Embodiment 57. The use of any one of Embodiments 54-56, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4is to be administered once a day, twice a day, or three times a day to the subject to achieve the total daily dose.
[0493] Embodiment 58. The use of any one of Embodiments 54-57, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject as a tablet or as an oral suspension.
[0494] Embodiment 59. The use of any one of Embodiments 35-58, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject in combination with one or more additional therapeutic agents.
[0495] Embodiment 60. The use of Embodiment 59, wherein the one or more additional therapeutic agents comprise growth hormone, risperidone, aripiprazole, trofinetide, atomoxetine, guanfacine, clonidine, viloxazine, haloperidol, pimozide, aripiprazole, onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, zolpidem, phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufmamide, clobazam, everolimus, cannabidiol, sapropterin hydrochloride, pegvaliase- pqpz, tasimelteon, ganaxolone, acetazolaminde, 4-aminopyridine, fampridine, flunarizine, and / or topiramate.
[0496] Embodiment 61. The use of any one of Embodiments 35-60 comprising administering N-acetyl-L-leucine to the subject.
[0497] Embodiment 62. The use of any one of Embodiments 1-60 comprising administering N-acetyl-L-leucine-2,3,3,4-d4 to the subject.
[0498] Embodiment 63. The use of any one of claims 1-62, wherein the N-acetyl-L- leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 24 weeks.
[0499] Embodiment 1A. Use of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 in the manufacture of a medicament for treating or preventing a disorder, or a clinical manifestation thereof, in a subject in need thereof, wherein N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to normalize the nuclear TFEB concentration and / or the TFEB nuclear-to-cytoplasmic (N:C) ratio in a nucleated cell of the subject by:
[0500] (i) increasing the nuclear TFEB concentration and / or TFEB N: C ratio relative to an aberrantly low basal nuclear TFEB concentration and / or TFEB N: C ratio; or
[0501] (ii) decreasing the nuclear TFEB concentration and / or TFEB N: C ratio relative to an aberrantly high basal nuclear TFEB concentration and / or TFEB N: C ratio,
[0502] wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease.
[0503] Embodiment 2A. The use of Embodiment 1A, wherein the administering normalizes the nuclear TFEB concentration in a cell of the subject by increasing the nuclear TFEB concentration relative to the basal nuclear TFEB concentration.
[0504] Embodiment 3A. The use of Embodiment 1 A, wherein the administering normalizes the nuclear TFEB concentration in a cell of the subject by decreasing the nuclear concentration of TFEB relative to the basal nuclear TFEB concentration.
[0505] Embodiment 4A. The use of Embodiment 1A, wherein the administering normalizes the nuclear TFEB N: C ratio in a cell of the subject by increasing the nuclear TFEB N: C ratio relative to the basal nuclear TFEB N: C ratio.
[0506] Embodiment 5A. The use of Embodiment 1A, wherein the administering normalizes the nuclear TFEB N:C ratio in a cell of the subject by decreasing the nuclear TFEB N:C ratio relative to the basal nuclear TFEB N:C ratio.
[0507] Embodiment 6A. The use of Embodiment 2A, wherein the nuclear TFEB concentration is increased relative to the basal nuclear TFEB concentration by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more; or the use of Embodiment 3A, wherein the nuclear TFEB concentration is decreased relative to the basal nuclear TFEB concentration by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more.
[0508] Embodiment 7 A. The use of Embodiment 4A, wherein the nuclear TFEB N:C ratio is increased relative to the basal nuclear TFEB N:C ratio by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more; or the use of Embodiment 5, wherein the nuclear TFEB N:C ratio is decreased relative to the basal nuclear TFEB N:C ratio by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more.
[0509] Embodiment 8A. The use of any one of Embodiments 1A-7A, wherein the N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to treat the disorder in the subject.
[0510] Embodiment 9A. The use of any one of Embodiments 1A-7A, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to treat the clinical manifestation of the disorder in the subject.
[0511] Embodiment 10A The use of any one of Embodiments 1A-7A, wherein the N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to prevent the disorder in the subject.
[0512] Embodiment 11A. The use of any one of Embodiments 1A-7A, wherein the N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to prevent a clinical manifestation of the disorder in the subject.
[0513] Embodiment 12A. The use of any one of Embodiments 1A-11A, wherein the disorder is a metabolic disorder.
[0514] Embodiment 13A. The use of Embodiment 12A, wherein the metabolic disorder is any one or more of the disorders listed in Table 1A.
[0515] Embodiment 14A. The use of Embodiment 13 A, wherein the metabolic disorder is a lysosomal storage disease.
[0516] Embodiment 15A. The use of Embodiment 14A, wherein the lysosomal storage disease is Farber disease, Krabbe disease, galactosialidosis, Fabry disease; Schindler disease, β-galactosidase / GM1 gangliosidosis, Sandhoff disease, Tay-Sachs disease, Gaucher disease Type I, Gaucher disease Type II, Gaucher disease Type II, lysosomal acid lipase deficiency, Niemann-Pick disease Type A, Niemann-Pick disease Type B, sulfatidosis, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome Types A-D, Morquio, Maroteaux-Lamy syndrome, Sly syndrome, hyaluronidase deficiency,; Mucolipidosis, Types I-IV, Niemann-Pick disease Type C, Niemann-Pick disease Type D, neuronal ceroid lipofuscinoses Types 1-10, Wolman disease, alpha-mannosidosis, beta-mannosidosis, aspartylglucosaminuria; fucosidosis, cystinosis, pycnodysostosis, Salla disease / sialic acid storage disease, infantile free sialic acid storage disease, Pompe disease, Danon disease, mucopolysaccharidosis, or cholesteryl ester storage disease.
[0517] Embodiment 16A. The use of any one of Embodiments 1A-11A, wherein the disorder is a neurodegenerative disorder.
[0518] Embodiment 17A. The use of Embodiment 16A, wherein the neurodegenerative disorder is any one or more of the disorders listed in Table 2A.
[0519] Embodiment 18A. The use of any one of Embodiments 1A-11A, wherein disorder is a neurodevelopmental disorder.
[0520] Embodiment 19A. The use of Embodiment 18A, wherein the neurodevelopmental disorder is any one or more of the disorders listed in Table 3A, any one or more of the CACNA-related neurodevelopmental disorders listed in Table 3B, or any one or more of the CACNA1A-related neurodevelopmental disorders listed in Table 3C.
[0521] Embodiment 20A. The use of any one of Embodiments 1A-11A, wherein the disorder is a neurological disorder.
[0522] Embodiment 21A. The use of Embodiment 20A, wherein the neurological disorder is one or more of the disorders listed in Table 4A.
[0523] Embodiment 22A. The use of any one of Embodiments 1A-11A, wherein the disorder is cancer.
[0524] Embodiment 23A. The use of Embodiment 22A, wherein cancer is one or more of the cancers listed in Table 5A and / or Table 5B.
[0525] Embodiment 24A. The use of any one of Embodiments 1A-11A, wherein the disorder is a defective autophagy disease.
[0526] Embodiment 25A. The use of Embodiment 24A, wherein defective autophagy disease is infectious disease, skeletal muscle disease, systemic lupus erythematosus, or kidney disease.
[0527] Embodiment 26A. The use of any one of Embodiments 1-25, wherein a total dose of about 1 g to about 10 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject per day.
[0528] Embodiment 27A. The use of Embodiment 26A, wherein a total dose of about 1 g to about 8 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject per day.
[0529] Embodiment 28 A. The use of Embodiment 27A, wherein a total dose of about 1 g to about 5 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject per day.
[0530] Embodiment 29A. The use of any one of Embodiments 26A-28A, wherein N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered once a day, twice a day, or three times a day to the subject to achieve the total daily dose.
[0531] Embodiment 30A. The use of any one of Embodiments 26A-29A, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject as a tablet or as an oral suspension.
[0532] Embodiment 31A. The use of any one of Embodiments 1A-30A, wherein N- acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject in combination with one or more additional therapeutic agents.
[0533] Embodiment 32A. The use of Embodiment 31A, wherein the one or more additional therapeutic agents comprise growth hormone, risperidone, aripiprazole, trofinetide, atomoxetine, guanfacine, clonidine, viloxazine, haloperidol, pimozide, aripiprazole, onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, zolpidem, phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufmamide, clobazam, everolimus, cannabidiol, sapropterin hydrochloride, pegvaliase- pqpz, tasimelteon, ganaxolone, acetazolaminde, 4-aminopyridine, fampridine, flunarizine, and / or topiramate.
[0534] Embodiment 33A. The use of any one of Embodiments 1A-32A, wherein N- acetyl-L-leucine is to be administered to the subject.
[0535] Embodiment 34A. The use of any one of Embodiments 1A-32A, wherein N- acetyl-L-leucine-2,3,3,4-d4 is to be administered to the subject.
[0536] Embodiment 35A. The use of any one of Embodiments 1A-34A, wherein the nucleated cell is a neuron, glial cell, hepatocyte, myocyte, fibroblast, peripheral blood mononuclear cell (PBMC), or macrophage.
[0537] Embodiment 36A. The use of any one of Embodiments 1A-35A, wherein the nuclear TFEB concentration is determined using an enzyme-linked immunosorbent assay (ELISA).EXAMPLESExample 1Cell Culture and Transfection
[0538] HeLa cells were cultured in DMEM supplemented with 10% v / v FCS, 2 mM glutamine, 100 U / ml penicillin and 100 pg / ml streptomycin, at 37°C under 5% CO2. Cells were trypsinized and seeded onto CellView Slides (Greiner Bio-One).
[0539] One to two days after sub -culturing, cells were transiently transfected with JetPEI reagent in a 5:2 ratio with DNA. Per well, cells were transfected with 100 ng TFEB tagged on its C-terminus with either EGFP (Addgene plasmid # 38119) or mScarlet3 (produced in-house) for 4-6 h. Transfection medium was removed and replaced with fresh DMEM with or without agents and incubated overnight at 37°C. The next day, TFEB-EGFP- expressing cells were loaded for 1 h at 37°C with NucSpot® Live 650 Nuclear Stain (Biotium) in the continued presence of drugs as required. Cells were then transferred into extracellular medium (ECM, mM: 121 NaCl, 5.4 KC1, 0.8 MgCh, 1.8 CaCh, 6 NaHCOs, 25 HEPES, 10 glucose) that maintained the overnight treatment reagents and these live cells were imaged immediately.
[0540] Cells expressing TFEB -mS carl et3 were treated with similar reagent protocols but could be fixed with 4% PF A (in PBS) after reagent treatments. After fixation and permeabilization (0.1% Triton X-100 in PBS for 15 min), nuclei were labelled with NucSpot® Live 488 Nuclear Stain (Biotium) for 10 min in PBS and imaged within 2 days.Microscopy
[0541] Cells were imaged at room temperature using a Nikon AIR laser-scanning confocal equipped with a Plan ApoVC 20x DIC N2 (NA: 0.75) or Plan Fluor 40x oil DIC HN2 (NA: 1.3) objective. In Channel-Series mode, green, red or far-red fluorophores were alternately excited (ex / em): 488 / 525 nm, 561 / 595 nm, and 640 / 700 nm respectively.Nuclear Translocation Analysis
[0542] To quantify the translocation of fluorescent TFEB from the cytoplasm to the nucleus, the Pearson’s Correlation Coefficient between TFEB and the orthogonal nuclear stain in single cells was analyzed. Cells with a cytoplasmic location have negative coefficients, whereas nuclear translocation is reflected by positive coefficients. Cells withnuclear TFEB (partial or completely translocated) were defined as having a Pearson’s coefficient >0, and the number of cells satisfying this criterion expressed as a percentage of the total number.In-Cell Western for detection of LAMP 1
[0543] HeLa cells were seeded into a 96-well flat-bottom micro clear black plate (Greiner Bio-one). Following treatment with agents, cells were fixed with 4% PFA and permeabilised with 0.1% Triton X-100 for 10 min. Following block in Odyssey blocking buffer (LICORbio), cells were incubated with mouse anti-LAMPl antibody (H4A3, DSHB at The University of Iowa) and was detected using IRDye 800CW goat anti-mouse IgG secondary antibody (LICORbio). Cells were co-stained with CellTag 700 Stain for In-Cell Western Assays (LICORbio) for accurate normalization to cell number. Cells were scanned using an Odyssey M Imaging System in the 700 and 800 nm channels and analysed using Empiria Studio (LICORbio).Reverse Transcription Quantitative PCR (RT-qPCR)
[0544] Total RNA was extracted from HeLa cells using a RNeasy Plus Mini kit (Qiagen) following the manufacturer's instructions. cDNA was prepared using an iScript cDNA synthesis kit in a MyCycler Thermal Cycler system (both Bio-Rad). qPCR was then performed with a CFX96 Real-Time PCR instrument (Bio-Rad) using PowerUp SYBR Green (Applied Biosystems) and the primer pairs specified in Tables 5 A and 5B. Threshold cycle (Ct) values were normalised to the reference gene 13- actin using the comparative Ct method, on a scale where P-actin expression equals 10,000 units.Table 5 A. Primer sequences (forward) for RT-qPCR, sourced from OriGene and PrimerBankTable 5B. Primer sequences (reverse) for RT-qPCR, sourced from OriGene and PrimerBank
[0545] N-Acetyl-L-leucine acts as a pro-drug to generate high concentrations of L-leucine in cells because it is a substrate for MCT transporters. Churchill et al. 2021. et al. Sci Rep.11:15812. In a first series of experiments, it was investigated whether HeLa cells express the key components of the N-acetyl-L-leucine transport mechanisms. It was found that HeLa cells express the minimum necessary apparatus for a response to N-acetyl-L-leucine. Expression patterns of monocarboxylate transporters (MCT1, MCT2, MCT3, MCT4) and the aminoacylase 1 enzyme (ACY1) were determined by RT-qPCR Expression was normalised to P-actin, on a scale where B-actin expression equals 10,000 arbitrary' units, n = 2. Fig. 1 shows that HeLa cells contain transcribed mRNA for several monocarboxylate transporter types, including MCT1 1, as well as an acylase demonstrated to hydrolyze N- acetyl groups from amino acids. Bloch and Borek. 1946. J Biol Chem. 164:483; Bloch and Rittenberg. 1947. J Biol Chem. 169:467-476. The resulting L-leucine enters metabolic pathways to increase ATP synthesis, but also acts to clear stored lipids from lysosomes. Kaya et al. 2020. J Clin Med. 9.
[0546] To test for a direct effect on lysosomal function, the effect of treating HeLa with N-acetyl-L-leucine on the translocation of TFEB-GFP from the cytoplasm to the nucleus was examined. This is a hallmark for the activation of this transcription factor. Settembre et al. 2012. EMBO J. 31: 1095-1108. It was found that extracellular incubation of cells with N-acetyl-L-leucine caused the appearance of TFEB-GFP in the nucleus during a 24 hour incubation. Fig. 2.
[0547] The effect was concentration-dependent with effects seen at the sub-millimolar range, which coincides with plasma concentrations observed in mice dosed with therapeutic concentrations of N-acetyl-L-leucine. Churchill et al. 2021. et al. Sci Rep. 11:15812. Expression of a constitutively activated form of calcineurin in the cytoplasm drove all the TFEB-GFP into the nucleus, consistent with it effect to dephosphorylate the whole cytoplasmic pool of TFEB. Similarly, treatment with the SERCA pump inhibitor, thapsigargin, which produces a large global increase in intracellular free Ca2+also promoted a significant nuclear translocation of TFEB (Medina et al. 2015. Nat Cell Biol. 17:288- 299), similar to the effect of N-acetyl-L-leucine (500pM). Fig. 3.
[0548] The ECso for this effect was approximately 200 pM, see Fig. 4, and the maximum effect was around 60% of the total TFEB being translocated to the nucleus at 1 mM. The results shown in Figs. 1 and 2 are for transfected HeLa cells, but essentially similar results were seen in U2OS cells, an osteosarcoma cell line. The onset of action of N-acetyl-L- leucine was rapid, with half-maximal effect seen within 60 min, see Fig. 5, during continuous application of the drug, indicating that constant N-acetyl-L-leucine over-rides any effect of L-leucine generated by metabolism of N-acetyl-L-leucine. Importantly, this effect was not shared by L-leucine over a similar concentration range, see Fig. 6, which is the major metabolite of N-acetyl-L-leucine through the action of amino acid acylases (Birnbaum et al., 1952), demonstrating that this effect required the acetylation of L-leucine. This effect would only be transient since N-acetyl-L-leucine is converted to L-leucine by cellular acylases. Bloch and Rittenberg. 1947. J Biol Chem. 169:467-476; Churchill et al.2020. PLoS One. 15:e0229585.
[0549] N-acetyl-DL-leucine has also been suggested to have beneficial effects in lysosomal storage diseases (Kaya et al. 2020. J Clin Med. 9) and thus the effects of N-acetyl-L-leucine, N-acetyl D-leucine, and N-acetyl D-L-leucine on TFEB translocation to the nucleus were tested. See Fig. 7. N-acetyl-L-leucine caused a robust translocation of TFEB into the nucleus, but the D-enantiomer had no effect. Surprisingly, the N-acetyl DL-leucine also failed to activate TFEB translocation, indicating that the presence of the D-enantiomer in the racemic mixture antagonizes the effect of the L-enantiomer.
[0550] There is a downstream functional correlate of TFEB activation. As a master transcription factor, TFEB regulates lysosomal protein expression and lysosomal mass. Settembre et al., EMBO J. 31: 1095-1108 (2012). A lysosomal marker protein is lysosome-associated membrane protein 1 (LAMP1), a transmembrane protein expressed in lysosomes and late endosomes. Incubation of cells with NALL significantly increased the expression of LAMP 1. Briefly, HeLa cells were treated with 2 mM NALL for 18 hours, then processed for In-Cell Western analysis: endogenous LAMP1 was labelled with an anti -LAMP 1 antibody and stained with CellTag700 (for normalization to cell number). Data are expressed as the mean (LAMPl / CellTag700) ± SEM of 12 replicates, and significance determined by a paired t-test, with significance denoted by *** p< 0.001 compared to vehicle control (Ctrl), i.e. 0 mMNALL. Fig. 12. The LAMP1 gene has a CLEAR sequence in its promoter region, which affords regulation of its expression by TFEB.
[0551] TFEB is regulated in cells is by phosphorylation by the mTORC serine / threonine kinase complex Settembre et al. 2012. EMBO J. 31:1095-1108. Phosphorylation inactivates TFEB and favors its cytoplasmic localization by its interaction with 14-3-3 proteins Roczniak-Ferguson et al. 2012. Sci Signal. 5:ra42. Starvation of cells by reducing the levels of mTOR activators, principally L-leucine, inhibits the kinase activity of mTOR associated with its phosphorylation state at key amino acid residues, reducing mTOR activity to its basal state. HeLa cells were serum-starved: cells were washed twice with PBS and cultured for 18h in low serum (0.1% FCS)-containing medium. Cells were treated with 2 mM NALL for 0.5, 1, 2. 3, 4 hours in low serum-containing medium at 37 °C. For serum stimulation, cells were incubated for 15 min with 10% FCS-containing medium at 37 °C. Cells were pretreated for 30 min with 100 nM rapamycin or 100 nM Torin-2 before stimulation with serum. Reintroduction of fetal calf serum (FCS) containing nutrients activates mTOR as is associated with mTOR phosphorylation such as at serine 2448. Incubation of cells with known mTOR inhibitors, rapamycin (100 nM) or torin (100 nM) reduced the mTOR phosphorylated / mTOR non-phosphorylated ratio indicative of mTOR inhibition. Remarkably, after incubation with N-acetyl-L-leucine (2 mM) the mTOR phosphorylation ratio even more than torin, see Fig. 8, suggesting that it is a potent inhibitor of mTOR. This finding is consistent with the notion that by inhibiting mTOR, N-acetyl-L- leucine stimulation would therefore reduce the degree of phosphorylation of TFEB allowing it to translocate to the nucleus.
[0552] To investigate the effect of N-acetyl-L-leucine on TFEB activation in cells with an NPC phenotype, HeLa cells were first incubated overnight with U18666A, an inhibitor of the NPC1 protein (Lu et al. 2015. Elife. 4). As previously reported (Du et al., eLife,https: / / doi. Org / 10.7554 / eLife.103137.2), NFC was also associated with a compensatory increase in TFEB nuclear translocation in HeLa cells, see Fig. 9, which was similar to treatment of cells with N-acetyl-L-leucine (2 mM). Surprisingly, treatment of the HeLa cells with the U18666 A-induced phenotype, reduced the extent of TFEB activation in these cells. In another experiment, N-acetyl-L-leucine activated nuclear TFEB translocation in control (wild-type) cells and reduced nuclear TFEB in Npcl^ cells (a model of Niemann- Pick disease Type C). See Fig. 11.
[0553] Without wishing to be bound by any particular theory or mechanism of action, Fig. 10 summarizes the key actions of N-acetyl-L-leucine and the key signaling pathways that it modulates which are reflected in the changes in cellular responses seen. Step 1: N-Acetyl-L-leucine (NALL) is transported into cells via the MCT transporter family. Step 2: N-Acetyl-L-leucine inhibits the activity of the mTORC complex and reduces TFEB phosphorylation. Step 3: Inhibition of mTOR relives its inhibition on Ca2+release channels expressed in lysosomes leading to Ca2+release by TPC2 and / or TRPML1 allowing regulating of vesicular fusion and trafficking (Step 4). Step 5: Lysosomal Ca2+release activates calcineurin (CN) to dephosphorylate TFEB and remove its ability to bind 14-3-3 proteins allowing it to translocate to the nucleus (Step 6). Step 7: TFEB binds to CLEAR gene promoters and activates lysosomal and autophagic gene expression. Step 8: This increases lysosomal biogenesis, autophagy and lysosomal exocytosis leading to cellular clearance of stored lysosomal material (Step 9). Step 10: N-Acetyl-L-leucine is metabolised to L-leucine that reactivates mTOR resulting in TFEB inactivation through phosphorylation. Step 11: L-leucine enters metabolic pathways, where it normalizes energy metabolism where it (e.g., increases mitochondrial ATP production, reduces oxidative stress (Step 12). The secondary knock-on effects of restoring mitochondrial and lysosomal function include normalizing neuronal membrane potential and thereby synaptic transmission, thereby impacting fundamental developmental processes such as neuronal differentiation, migration, and synapse formation as well as moderating neuroinflammation, protecting against further neurodegeneration.Discussion
[0554] The goal of this study was to elucidate of the cellular mechanisms of action of N-acetyl-L-leucine. It was unexpectedly discovered that N-acetyl-L-leucine stimulates the translocation of TFEB to the nucleus, and that this effect was not seen with L-leucine.
[0555] It has previously been shown that N-acetyl-L-leucine improves the bioenergetics of neurons by enhancing ATP production and activity of the citric acid cycle as well as reducing lysosomal storage of lipid. Kaya et al., Brain Commun. 2020, 3, fcaal48. Further, the efficacy of N-acetyl-L-leucine is dependent on the acetyl moiety which renders the drug a substrate for high capacity MCT transporters, which accumulates in cells and is transformed into L-leucine by acylases which have been shown to be expressed in HeLa cells. Churchill et al., Sci. Rep. 2021, 77, 15812. Such high concentrations of L-leucine would have been expected to stimulate mTOR, but to the contrary it was found that treatment of cells first directly inhibited mTOR before conversion to L-leucine to reverse this effect. Wolfson et al., Science 2016, 357, 43-48. N-acetyl leucine amide has also been reported to inhibit mTOR. Hidayat et al., Biochem. Biophys. Res. Commun. 2003, 301, 417- 423. However, this transient inhibition is sufficient to suppress the inhibitory effect of mTOR-mediated TFEB phosphorylation which inhibits TFEB translocation to the nucleus to activate the CLEAR network of lysosomal and autophagy genes. This suggests that N-acetyl-L-leucine has dual effects on both mitochondria and lysosomal pathways to improve cellular function. Deus et al., Trends Mol. Med. 2020, 26, 71-88. These findings align with a recent report that TFEB activation can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. Du et al., eLife, https: / / doi. Org / 10.7554 / eLife.103137.2.
[0556] The effects of N-acetyl-L-leucine observed occur at concentrations which match measured plasma concentrations during "therapeutic" dosing. Churchill et al., PLOS One 2020, 75, e0229585.
[0557] Specifically these findings demonstrate that N-acetyl-L-leucine at therapeutically relevant concentrations enhances TFEB activation through multiple cellular pathways thereby improving lysosomal biogenesis and function. The effect of N-acetyl-L-leucine was stereospecific in that N-acetyl-D-leucine did not activate TFEB nuclear translocation. Remarkably, N-acetyl-DL-leucine was also without effect, indicating that the presence of equimolar N-acetyl-D-leucine inhibited the effect of N-acetyl-L-leucine. Since N-acetyl-DL-leucine, which is sold as the vertigo treatment, tanganil®. Vibert and Vidal 2001. Eur J Neurosci. 13:735-748), lacks effect on an important lysosomal signaling pathway which improves lysosomal function, this would correlate with the significant greater efficacy of N-acetyl-L-leucine over N-acetyl-DL-leucine for the treatment oflysosomal storage diseases. Furthermore, the fact that N-acetyl D-leucine is not a substrate for acylases precludes its conversion to L-leucine. Kaya et al. 2021. Brain Commun.3:fcaal48. Thus, N-acetyl-L-leucine may have considerable benefits over the N-acetyl- DL-leucine for the treatment of lysosomal storage diseases.
[0558] N-Acetyl-L-leucine's ability to enhance TFEB nuclear translocation and lysosomal function indicates its utility in treating a broad range of disorders characterized by lysosomal and mitochondrial dysfunction. For example, increases in TFEB have been suggested to enhance the degradation of Ap plaques in mouse hippocampus by 40%, which may be relevant for human disease, since in preclinical models, a 25% Ap reduction correlates with a meaningful improvement in cognitive deficits. Xiao et al., J. Neurosci.2015, 35, 12137-12151; Singh et al., J. Alzheimers Dis. Rep. 2024, 8, 371-385. It has also been shown that TFEB activation promotes the degradation of Tau proteins, leading to a reduction in Tau aggregates and that a small molecule activator of TFEB ameliorates betaamyloid precursor protein and Tau pathology in Alzheimer's disease models. Polito et al., EMBO Mol. Med. 2014, 6, 1142-1160; Song et al., Autophagy 2016, 12, 1372-1389. Studies have confirmed that TFEB can reduce the deposition of toxic Tau aggregates, which represents a neuroprotective effect. TFEB enhances the lysosomal degradation of Tau, thereby reducing the formation of toxic aggregates. These mechanisms are crucial for the prevention of tauopathies, such as those observed in Alzheimer's and other neurodegenerative diseases. TFEB also helps regulate the secretion of abnormal Tau, which promotes cellular clearance and can prevent further neuronal loss. Furthermore, TFEB has been shown to have a protective effect against alpha-Synuclein aggregates, which are typically associated with Parkinson's disease. TFEB promotes autophagy and the lysosomal degradation of alpha-Synuclein oligomers, which can reduce the toxic effects of these aggregations. Decressac et al., Proc. Natl. Acad. Sci. U. S. A. 2013, 110, el817-1826. In animal models, TFEB overexpression resulted in nearly complete prevention of dopaminergic neuronal loss, indicating the neuroprotective effect of TFEB. Moreover, TFEB overexpression in a mouse model increases dopamine release by 20%, reverses the atrophy of dopaminergic neurons, and enhances protein biosynthesis through mTORCl phosphorylation. Torra et al., Mol. Ther. 2018, 26, 1552-1567.
[0559] Excessive TFEB activation is associated with tumorigenesis. Chen et al., Cell Death Discov. 2024, 10, 84; Lin et al., Proc. Natl. Acad. Sci. U. S. A. 2023, 120, e2213670120.N-acetyl-L-leucine only transiently activates TFEB due to its metabolism to L-leucine, mitigating against the effects of excessive TFEB stimulation. Churchill et al., PLOS One 2020, 75, e0229585, and in diseased cell where TFEB is excessively activated, N-acetyl-L- leucine reduces or normalizes its levels of activation. See Fig. 8 and Fig. 11).Example 2
[0560] Subjects with a disorder listed in Table 1A, Table 2A, Table 2B, Table 3A, Table 3B, Table 3C, or Table 4A will be treated with about 1 g to about 30 g of N-acetyl-DL- leucine per day or about 1 g to about 30 g of N-acetyl-L-leucine per day and, optionally, one or more additional therapeutic agents.
[0561] Symptoms of disorders will be documented prior to administration and then at defined intervals after administration of N-acetyl-DL-leucine or N-acetyl-L-leucine. Subjects and / or caregivers will keep a daily diary to record medication usage, adverse events, e.g., seizure type and frequency, sleep habits, and quality of life measures, including communication, behaviour, coordination, sensory, and GI issues.
[0562] The following assessments may be used to score and document the subject's neurological symptoms.Intellectual Assessment
[0563] The Wechsler Preschool and Primary Scale of Intelligence-Fourth Edition (WPPSL IV) is an individualized, standardized intelligence test for children aged from 2 years 6 months to 7 years 7 months. At ages from 2 years 6 months to 3 years 11 months, the WPPSI-IV subtests are organized as follows: 1) The Verbal Comprehensive Index (VCI) from the Receptive Vocabulary’ and Information subtests, 2) The Visual Spatial Index (VSI) from the Block Design and Object Assembly subtests, and 3) The Working Memory Index (WMI) from the Picture Memory and Zoo Locations subtests. One supplementary subtest - Picture Naming - is provided.
[0564] At ages from 4 years to 7 years 7 months, the WPPSI-IV subtests are organized as follows: 1) The VCI from the Information and Similarities subtests, 2) The VSI from the Block Design and Object Assembly subtests, 3) The Fluid Reasoning Index (FRI) from the Matrix Reasoning and Picture Concepts subtests, 4) The WMI from the Picture Memory and Zoo Locations subtests, and 5) The Processing Speed Index (PSI) from the Bug Search and Cancellation subtests. Five supplementary subtests - Vocabulary, Animal Coding,Comprehension, Receptive Vocabulary, and Picture Naming - are provided. The Wechsler Intelligence Scale for Children--- Fourth Edition (WISC-IV) is the latest version of the most frequently used intelligence test for children aged from 6 years to 16 years 11 months. The WISC-IV core subtests produce four indexes: 1) The VCI from the Similarities, Vocabulary, and Comprehension subtests, 2) The Perceptual Reasoning Index (PRI) from the Block Design, Picture Concepts, and Matrix Reasoning subtests, 3) The WMI from the Digit Span and Coding Subtests, and 4) The PSI from the Letter-Number Sequencing and Symbol Search subtests. Five supplementary subtests - Information, Word Reasoning, Picture Completion, Arithmetic, and Cancellation - are provided to substitute for core subtests as necessary. Children with ADHD are more likely to receive low scores on the WMI and PSI. Children with high-functioning autism scored above normal on the VCI and PRI, but scored below normal on the WMI and PSI.
[0565] The Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) is an individualized, standardized intelligence test for adults and older adolescents. The WAIS- IV core subtests produce four indexes: 1) The VCI from the Similarity, Vocabulary, and Information subtests, 2) The PRI from the Block Design, Matrix Reasoning, and Visual Puzzles subtests, 3) The WMI from the Digit Span and Arithmetic subtests, and 4) The PSI from the Symbol Search and Coding subtests. Five suppiemen tary subtests - Letter- Number Sequencing, Figure Weights, Comprehension, Cancellation, and Picture Completion -- are provided. (Oh, Mi-Young, " Psychological Assessment in Neurodevelopmental Disorders," Hanyang Med Rev, 36:72-77 (2016)).Neuropsychological Assessment
[0566] The omission, commission, and latency errors of the Continuous Performance Test (CPT) are intended to measure visual / auditory sustained attention, vigilance, and impulsivity. The color-word score of the Stroop test is intended to measure response inhibition. The Trail Making Test (TMT) has two versions: 1) TMT A measures visual search and perceptual motor speed, 2) TMT B measures executive function and set shifting. The WMI of the Wechsler intelligence scales measures attention and working memory.
[0567] The Wisconsin Card Sorting Test (WCST) is the most widely used executive function test throughout the world. It measures cognitive flexibility and set shifting. Subjects are asked to sort cards based on an undisclosed sorting rule (by either shape, color, or number). They are given feedback about whether they are sorting correctly or- Ill -incorrectly. Once the individual has correctly completed 10 sorts, the rule is changed without any warning or comment, and the individual is expected to shift to a new sorting set. The most relevant score is the number of perseverative responses, defined as the number of sorts that use an old sorting rule despite feedback that it is incorrect. (Oh, Mi- Young, " Psychological Assessment in Neurodevel opmental Disorders," Hanyang Med Rev, 36:72-77 (2016)).Adaptive Behavior Assessment
[0568] The most widely used scale to measure adaptive behaviour is the Vineland Adaptive Behavior Scale (VABS). The revised edition of the VABS, the Vineland Adaptive Behavior Scale-2nd Edition (Vin-eland-II), was published in 2005. Vineland-II is available in two forms: interview and parent / caregiver rating, both forms have the same questionnaire content. For the interview form, a trained examiner interviews the child's primary caregiver using a semi -structured interview format and measures the adaptive behaviors of the child. For the parent / caregiver rating, the child's primary caregiver completes the questionnaire and assesses their child's adaptive behaviors. Similar to the VABS, the Vineland-II measures adaptive functioning in 4 domains: communication, daily-living skills, socialization, and motor skills. The motor skills domain is only applicable to children under 6-years-old. A composite score of adaptive behavior is calculated as the sum of the standard scores from the 4 domains. (Oh, Mi- Young, " Psychological Assessment in Neurodevelopmental Disorders," Hanyang Med Rev, 36:72-77 (2016)).Autism Diagnostic Assessment
[0569] The Childhood Autism Rating Scale (CARS) is a 15-item structured structured observation tool that assesses the child's symptoms based on direct observation of the behavior. Each item is rated on a 7-point scale and the scores range from 0 to 60. To be diagnosed with ASD, the total score should be higher than 30, however, for adolescents, a lower cut-off score is suggested. The CARS was designed to measure and assess development through direct observation. The observed behavior of the children is assessed and compared to that of typically developed children at the same age. If abnormal behavior is observed, the child's age, characteristics, frequency of the behavior, and severity of the behavior should be collected when considering a diagnosis.
[0570] The Autism Diagnostic Interview-Revised (ADI-R) is a comprehensive parentinterview tool that is used to assess symptoms of ASD. The ADI-R is administered by trained clinicians in a semi -structured interview format. Clinicians gather information through parent's report of the child's noticeable behavior and development. The ADI-R questionnaire comprises questions that distinguish ASD from other developmental disorders, and it measures the following 3 domains: social interaction, communication, and stereotyped, repetitive, and fixated behavior patterns. Additionally, the ADI-R provides algorithm scores.
[0571] The Social Communication Questionnaire (SCQ), which is based on the ADI-R, works as a parent-report screening-instrument to diagnose individuals at risk for ASD. The SCQ is a 40-item questionnaire that was revised to help parents understand without any further elaboration needed. There are two versions of the SCQ: lifetime and current. The lifetime version is typically used for distinguishing individuals who might have ASD, or for an evaluative diagnosis. The current version is more suitable to assess changes in symptoms over time. A cut-off score over 15 suggests the individual is likely to have ASD. (Oh, Mi-Young, " Psychological Assessment in Neurodevelpomental Disorders," Hanyang Med Rev, 36:72-77 (2016)).Psychiatric Comorbidities
[0572] The Child Behavior Checklist (CBCL) is widely used to assess emotional and behavioral problems during preschool, childhood, and adolescence. The CBCL is standardized in many different languages and are cost-effective when compared to interviews because the survey is completed by the primary caregivers.
[0573] The CBCL Preschool Form is intended for preschoolers between 1.5-5 years old.The primary caregiver rates the preschooler on a scale from 0 to 2 for each question. Items are scored on 3 main scales including internalizing problems, externalizing problems, and total behavior problems, and 7 sub-scales including emotional reactivity, depression / anxiety, social withdrawal, somatic symptoms, sleeping problems, attention problems, and aggressive behavior. The CBCL School-Age Form measures various emotional and behavioral problems among children and adolescents between 6-18 years old. The CBCL is conducted by the primary caregiver who rates the child or adolescent on a scale from 0 to 2 for each question. Problematic behavior syndrome is rated on 3 main- scales of internalizing, externalizing, and total behavior problems, and 8 sub-scales ofsocial withdrawal, somatic symptom, depression / anxiety, social immaturity, logic-based problems, attention problems, aggressiveness, and rule breaking. (Oh, Mi-Young, " Psychological Assessment in Neurodevelpomental Disorders," Hanyang Med Rev, 36:72- 77 (2016)).Other Assessments
[0574] Changes in seizures, sleep, communication, behaviors, and physical abilities will be assessed before and after treatment with N-acetyl leucine using a multi-question form. The ratings will also be reported on a scale from +5 (really improved) to -5 (much worse), with 0 being the same as baseline. Cumulative ratings from each category will be generated.Example 3Acetyl-Leucine Improves Cerebellar Dysarthria in MSA-C
[0575] A 53-year-old female patient had progressive problems coordinating her hand and arm movements, gait instability, and slurred speech. Neurological examination revealed marked dysarthrophonia with scanning speech, limb and trunk ataxia, and a cerebellar oculomotor disorder with saccadic pursuit and bilateral gaze-evoked nystagmus. As the disease progressed, the patient developed urge incontinence and orthostatic dysregulation. Magnetic resonance imaging (MRI) showed progressive cerebellar atrophy and T2 / FLAIR sequence indicated a hyperintensity of the pons in the shape of a cross, also known as the "hot cross bun sign". The diagnosis of multiple system atrophy with predominant cerebellar ataxia (MSA-C) was made. According to the diagnostic criteria of the Movement Disorder Society (MDS), Wenning et al., Mov Disord. 2022;37(6): 1131-48, which were published later in 2022, this case met the definition of a "clinically established MSA." There were no approved therapies for MSA at that time.
[0576] The patient was treated N-acetyl-DL-leucine (5g / day). After 2 weeks, she reported a marked improvement in her speech. To objectively assess changes in speech performance during the text-reading tasks presented in the video, a quantitative analysis of key acoustic parameters across the two recordings using the Praat software was conducted. Reading duration decreased notably from 39.41 to 22.82 seconds. Total pause time was reduced by more than half (14.1 to 6.8 seconds), accompanied by fewer pauses (35 to 28), and shorter mean pause durations (402 to 243 ms), indicating more fluent speech. Additionally, pitchvariability increased (SD: 41.55 to 44.28 Hz) alongside greater intensity variability (SD: 13.70 to 15.65 dB), reflecting reduced speech monotony.Example 4
[0577] Human HeLa wild-type cells were compared against those in which the NPC1 gene is knocked out, which is a cellular model for NPC disease. The calcium content of lysosomes was assessed with a combination of drug mimetics of NAADP and PI,3,5P2 (a coregulator of TPC2), termed TPC2-A1N and TPC2-A1P, which activate TPC2 channels and empty them of calcium. The calcium fluxes from the lysosome were detected optically by use of a genetically-encoded calcium reporter functionally attached near the pore of the ion channel termed TPC2-G-GECO1.2. This gives a selective report of calcium release only from lysosomes, only via TPC2, and not from other sources.
[0578] In wild-type HeLa cells, after 12-hours of treatment with NALL, there was a significant reduction in lysosomal calcium. This effect was specific to the L-enantiomer. The D-enantiom er (NADL) had no effect. Fig. 13.
[0579] In NPC1- / -cells, there was significantly lower calcium in their lysosomes compared to wild-type control cells. But after treatment of cells with NALL, the lysosomal calcium content normalized to higher levels. Fig. 14.Example 5
[0580] The nuclear localization of TFEB was analyzed in fibroblast cells with or without treatment with NALL. All cells analyzed were purchased from the Coriell Institute for Medical Research. GM04912 cells were derived from a 4 month old male with Pompe disease, GM12932 cells were derived from a 9 month old female with Pompe disease, and GM20161 cells were derived from a two month old male with Pompe disease.
[0581] Fibroblast cells were transfected with TFEB-mScarlet and treated with either vehicle (control) or 2 mM NALL for 18 hours. Nuclei were labelled with NucSpot® Live 488 Nuclear Stain (Biotium) and colocalization of TFEB-mScarlet with the nucleus was quantified by Pearson's Coefficient (Table 7 and FIGs. 15A-15C). The baseline levels of nuclear TFEB as assessed in the vehicle treated were elevated similar to that the levels in NPC. Treatment with NALL reduced the levels of nuclear TFEB in each of the cells.Table 7References
[0582] Astanina, E., F. Bussolino, and G. Doronzo. 2021. Mol Oncol. 15:327-346.
[0583] Beninger, P. 2024. Clin Ther. 46: 1091-1092.
[0584] Birnbaum, et al. 1952. J Biol Chem. 194:455-470.
[0585] Bloch and Borek. 1946. J Biol Chem. 164:483.
[0586] Bloch and Rittenberg. 1947. J Biol Chem. 169:467-476.
[0587] Bremova-Ertl et al. 2024. N Engl J Med. 390:421-431.
[0588] Cang et al. 2013. Cell. 152:778-790.
[0589] Chang et al. 2020. BMC Biol. 18:8.
[0590] Chen et al. 2024. Cell Death Discov. 10:84.
[0591] Churchill et al. 2021. et al. Sci Rep. 11:15812.
[0592] Churchill et al. 2020. PLoS One. 15:e0229585.
[0593] Cortes and La Spada. 2019. Neurobiol Dis. 122:83-93.
[0594] Davis et al. 2020. EMBO J. 39:el04058.
[0595] Decressac et al. 2013. Proc Natl Acad Sci U S A. 110: E1817-1826.
[0596] Deus et al. 2020. Trends Mol Med. 26:71-88.
[0597] Du et al. 2024. eLife. https: / / en.wikipedia.org / wiki / Open_access.
[0598] Gu et al. 2022. Neurobiol Dis. 173:105855.
[0599] Hegdekar et al. 2021. Sci Rep. 11:9249.
[0600] Hidayat et al. 2003. Biochem Biophys Res Commun. 301:417-423.
[0601] Hoglinger et al. eLife 2015, 4, el0616.
[0602] Kaya et al. 2020. J Clin Med. 9.
[0603] Kaya et al. 2021. Brain Commun. 3:fcaal48.
[0604] Li et al. eZz / e 2016, 5, el9360.
[0605] Lin et al. 2023. Proc Natl Acad Sci U S A. 120:e2213670120.
[0606] Lloyd-Evans et al. 2008. Nat Med. 14:1247-1255.
[0607] Lu et al. 2015. Elife. 4.
[0608] Martello et al. 2020. Traffic. 21:354-363.
[0609] Medina et al. 2015. Nat Cell Biol. 17:288-299.
[0610] Mullard. 2024. Nat Rev Drug Discov. 23:804.
[0611] Napolitano and Ballabio. 2016. J Cell Sci. 129:2475-2481.
[0612] Oertel et al. 2024. Nat Commun. 15:7619.
[0613] Ogunbayo et al. 2018. Sci Signal. il.
[0614] Onyenwoke et al. 2015. Biochem J. 470:331-342.
[0615] Palmieri et al. 2011. Hum Mol Genet. 20:3852-3866.
[0616] Patterson and Platt. 2004. Biochim Biophys Acta. 1685:77-82.
[0617] Polito et al. 2014. EMBO Mol Med. 6: 1142-1160.
[0618] Puertollano et al. 2018. EMBO J. 37.
[0619] Roczniak-Ferguson et al. 2012. Sci Signal. 5:ra42.
[0620] Rosenbaum and Maxfield. 2011. J Neurochem. 116:789-795.
[0621] Sancak et al. 2010. Cell. 141:290-303.
[0622] Settembre et al. 2012. EMBO J. 31:1095-1108.
[0623] Singh et al. 2024. J Alzheimers Dis Rep. 8:371-385.
[0624] Song et al. 2016. Autophagy. 12:1372-1389.
[0625] Tifft et al. N Engl J Med. 390:467-470.
[0626] Torra et al. 2018. Mol Ther. 26:1552-1567.
[0627] Vibert and Vidal. 2001. Eur J Neurosci. 13:735-748.
[0628] Wolfson et al. 2016. Science. 351:43-48.
[0629] Xiao et al. 2015. J Neurosci. 35:12137-12151.
[0630] Zoncu et al. 2011. Science. 334:678-683.
[0631] Ataxias. In Handbook of the Cerebellum and Cerebellar Disorders, (Springer, Dordrecht), pp. 2193-267.
[0632] Available at: www.orpha.net / en / disease / detail / 1934.
[0633] Bozkaya-Yilmaz et al., Neurology. 2015;85(16): 1368-75.
[0634] Busner and Targum, Psychiatry (Edgmont). 2007 Jul;4(7):28-37. PMID: 20526405; PMCID: PMC2880930.
[0635] CACNA1A Foundation. Where in the World are CACNA1A Patients? 2024.Available from: www.cacnala.org / map-of
[0636] Calcraft, et al., (2009) Nature 459, 596-600.
[0637] Casey and Gomez,. Spinocerebellar Ataxia Type 6. GeneReviews [Internet].Available from: www.ncbi.nlm.nih.gov / books / NBK1140 / .
[0638] Churchill et al., (2002) Cell 111, 703-708.
[0639] Coen et al., (2012) J Cell Biol 198, 23-35. 10.1083 / jcb.201201076.
[0640] Davis et al., (2025) bioRxiv 2025.06.06.657607; doi:https: / / doi.org / 10.1101 / 2025.06.06.657607
[0641] Ducros et al., N Engl J Med. 2001 Jul 5;345(1): 17-24. doi:10.1056 / NEJM200107053450103. PMID: 11439943.
[0642] encephalopathy, 42. 2016. Available from:
[0643] Feil et al., JAMA Network Open. 2021;4(12):e2135841-e.
[0644] Feng and Yang, (2016) Messenger (Los Ange!) 5, 56-66. doi:10.1166 / msr.2016.1055.
[0645] Ferber- Viart et al., AudioL NeurootoL, 14, 17-25.
[0646] Fox et al., Ther Adv Rare Dis. 2024 Apr 25;5:26330040241245725. doi:10.1177 / 26330040241245725. PMID: 38681799; PMCID: PMC11047245.
[0647] Gancher and Nutt JG. Mov Disord 1986; 1:239 -253.
[0648] Gerndt et al., 2021. Brain Commun. 3:fcaal48.
[0649] Globas et al., J. Neurol. 2003;250:1482-7.
[0650] Gunther et al., PLoS ONE. 2015; DOI:10.1371 / joumal.pone.0120891.
[0651] Guterman et al., Neurology. 2016 Jun 7;86(23):e239-41. doi:10.1212 / WNL.0000000000002743. PMID: 27272039; PMCID: PMC4898315.
[0652] Harrison et al., Neuropharmacology. 2022 Dec l;220: 109262. doi:10.1016 / j.neuropharm.2022.109262. Epub 2022 Sep 22. PMID: 36154842.
[0653] Indelicato et al., Front Neurol. 2021 Mar 2; 12:639994. doi:10.3389 / fneur.2021.639994. PMID: 33737904; PMCID: PMC7960780.
[0654] Jen et al., Neurology 2004;62: 17-22.
[0655] Jen, Familial Hemiplegic Migraine. GeneReviews [Internet]. Available from: www.ncbi.nlm.nih.gov / books / NBK1388 / .
[0656] Kazemi et al., Iran J Child Neurol. 2014 Summer;8(3):6-ll. PMID: 25143767;PMCID: PMC4135274.
[0657] Kessi et al., Front Mol Neurosci. 2023 Jul 24;16: 1222321. doi:10.3389 / fnmol.2023.1222321. PMID: 37555011; PMCID: PMC 10406136. Park et al. 2024
[0658] Kilpatrick et al., (2016). Cell Calcium 59, 12-20. 10.1016 / j.ceca.2015.11.002.
[0659] Kiraly et al., 2025. BioRxiv. https: / / doi. Org / 10.l 101 / 2025.04.27.650877
[0660] Lopez-Rivera et al., Brain. 2020 Apr 1; 143(4): 1099- 1105. doi:10.1093 / brain / awaa051. PMID: 32168371; PMCID: PMC7174049.
[0661] Luo et al., PLoS Genet. 2017 Jul 24;13(7):el006905. doi:10.1371 / journal.pgen.1006905. PMID: 28742085; PMCID: PMC5557584.
[0662] Lykke Thomsen et al., Cephalalgia. 2002 Jun;22(5):361-75. doi: 10.1046 / j.1468- 2982.2002.00371.x. PMID: 12110112.
[0663] Martakis et al., Eur J Paediatr Neurol. 2025 Jan;54:64-67. doi:10.1016 / j.ejpn.2024.12.006. Epub 2025 Jan 2. PMID: 39765122.
[0664] Mochizuki et al., Acta Neuropathol (Berl) 2004; 108: 345-349.
[0665] Morgan et al., (2011) Biochem. J. 439, 349-374.
[0666] Moseley et al., Neurology. 1998;51:1666-71.
[0667] National Center for Biotechnology Information (NCIB). Developmental and epileptic
[0668] Orphanet, 2025. Orphanet: Early infantile developmental and epileptic encephalopathy.
[0669] Park et al., J Neurol. 2024 Oct;271(10):6888-6902. doi: 10.1007 / s00415-024- 12664-y. Epub 2024 Sep 3. PMID: 39225743; PMCID: PMC11447074.
[0670] Perlman, Neurologist 2004;10(5):275-89.
[0671] RareChromo. CACNAlA-related disorders. 2020 Available from:https: / / rarechromo. Org / media / singlegeneinfo / Single%20Gene%20Disorder%20Guides / C ACNAlA-related%20disorders%20QFN.pdf
[0672] Rudenskaya et al., Zh Nevrol Psikhiatr Im S S Korsakova. 2021; 121(12): 106-111.Russian, doi: 10.17116 / jnevro2021121121106. PMID: 35041321.
[0673] Sasaki et al., J Neurol 2003;250:373-375.
[0674] Schmitz-Hubsch et al., Neurology 2010;74:678-84.
[0675] Schmitz-Hubsch et al., Neurology. 2006;66:1717-20.
[0676] Schmitz-Hubsch et al., Neurology. 2008;71:486-92.
[0677] Strupp et al., J Neurol. 2013;260:2556-61.
[0678] Strupp et al., Neurotherapeutics. 2007 Apr;4(2):267-73. doi:10.1016 / j.nurt.2007.01.014. PMID: 17395137.
[0679] Suh et al., Annu Rev Biophys. 2008;37:175-95.
[0680] Sweatt, et al., J Comp Neurol. 2004;477(4):360-70.
[0681] Szymanowicz et al., Diseases. 2024 May 5;12(5):90. doi:10.3390 / diseasesl2050090. PMID: 38785745; PMCID: PMC11119137.
[0682] Taroni et al. (2013). Autosomal Dominant Spinocerebellar Ataxias and Episodic
[0683] Tighilet et al., Eur J Pharmacol. 2015;769:342-9.
[0684] Travaglini et al., Trends Pharmacol Sci (2025) 46:386-387. doi:10.1016 / j.tips.2025.02.003
[0685] Wenning et al., Mov Disord. 2022;37(6): 1131-48.
[0686] Williams et al., Neurobiol Dis. 2014 Jul;67:9-17. doi: 10.1016 / j.nbd.2014.03.001.Epub 2014 Mar 12. PMID: 24631719.
[0687] www.ncbi.nlm.nih.gov / medgen / 934683.
[0688] Zesiewicz et al., Neurology. 2012;78(8):545-50.
[0689] It is to be understood that the foregoing embodiments and exemplifications are not intended to be limiting in any respect to the scope of the disclosure, and that the claims presented herein are intended to encompass all embodiments and exemplifications whether or not explicitly presented herein.
[0690] All patents and publications cited herein are fully incorporated by reference in their entirety.
Claims
WHAT IS CLAIMED IS:
1. A method of regulating transcription factor EB (TFEB) activity in a cell of a subj ect in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 to the subject.
2. The method of claim 1, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 stimulates TFEB translocation from the cytoplasm of a cell to the nucleus of the cell compared to baseline.
3. The method of claim 1, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 reduces or normalizes TFEB levels in the nucleus of the cell compared to baseline.
4. The method of any one of claims 1-3, wherein the subject has a disorder, or a clinical manifestation thereof, wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease.
5. A method of treating or preventing a disorder, or a clinical manifestation thereof, in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 to the subject, wherein the administering normalizes the nuclear TFEB concentration and / or the TFEB nuclear-to- cytoplasmic (N: C) ratio in a nucleated cell of the subject by:(i) increasing the nuclear TFEB concentration and / or TFEB N: C ratio relative to an aberrantly low basal nuclear TFEB concentration and / or TFEB N: C ratio; or(ii) decreasing the nuclear TFEB concentration and / or TFEB N: C ratio relative to an aberrantly high basal nuclear TFEB concentration and / or TFEB N: C ratio, wherein the disorder is a metabolic disorder, a neurodegenerative disorder, a neurodevelopmental disorder, a neurological disorder, cancer, or a defective autophagy disease.
6. The method of claim 1, wherein the administering normalizes the nuclear TFEB concentration in a cell of the subject by increasing the nuclear TFEB concentration relative to the basal nuclear TFEB concentration.
7. The method of claim 5, wherein the administering normalizes the nuclear TFEB concentration in a cell of the subject by decreasing the nuclear concentration of TFEB relative to the basal nuclear TFEB concentration.
8. The method of claim 5, wherein the administering normalizes the nuclear TFEB N: C ratio in a cell of the subject by increasing the nuclear TFEB N: C ratio relative to the basal nuclear TFEB N: C ratio.
9. The method of claim 5, wherein the administering normalizes the nuclear TFEB N: C ratio in a cell of the subj ect by decreasing the nuclear TFEB N: C ratio relative to the basal nuclear TFEB N: C ratio.
10. The method of claim 6, wherein the nuclear TFEB concentration is increased relative to the basal nuclear TFEB concentration by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more; or the method of claim 7, wherein the nuclear TFEB concentration is decreased relative to the basal nuclear TFEB concentration by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more.
11. The method of claim 8, wherein the nuclear TFEB N: C ratio is increased relative to the basal nuclear TFEB N: C ratio by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more; or the method of claim 9, wherein the nuclear TFEB N: C ratio is decreased relative to the basal nuclear TFEB N: C ratio by about 2%, about 5%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more.
12. The method of any one of claims 4-11, wherein the N-acetyl-L-leucine or N-acetyl-L- leucine-2,3,3,4-d4is administered to treat the disorder in the subject.
13. The method of any one of claims 4-11, wherein N-acetyl-L-leucine or N-acetyl-L-leucine- 2,3,3,4-d4 is administered to treat the clinical manifestation of the disorder in the subject.
14. The method of claims 4-11, wherein the N-acetyl-L-leucine or N-acetyl-L-leucine-2, 3, 3, 4- d4is administered to prevent the disorder in the subject.
15. The method of any one of claims 4-11, wherein the N-acetyl-L-leucine or N-acetyl-L- leucine-2, 3,3, 4-d4 is administered to prevent a clinical manifestation of the disorder in the subject.
16. The method of any one of claims 4-15, wherein the disorder is a metabolic disorder.
17. The method of claim 16, wherein the metabolic disorder is any one or more of the disorders listed in Table 1A.
18. The method of claim 17, wherein the metabolic disorder is a lysosomal storage disease.
19. The method of claim 18, wherein the lysosomal storage disease is Farber disease, Krabbe disease, galactosialidosis, Fabry disease; Schindler disease, β-galactosidase / GM1 gangliosidosis, Sandhoff disease, Tay-Sachs disease, Gaucher disease Type I, Gaucher disease Type II, Gaucher disease Type II, lysosomal acid lipase deficiency, Niemann-Pick disease Type A, Niemann-Pick disease Type B, sulfatidosis, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome Types A-D, Morquio, Maroteaux-Lamy syndrome, Sly syndrome, hyaluronidase deficiency,; Mucolipidosis, Types I-IV, Niemann-Pick disease Type C, Niemann-Pick disease Type D, neuronal ceroid lipofuscinoses Types 1-10, Wolman disease, alpha-mannosidosis, beta- mannosidosis, aspartylglucosaminuria; fucosidosis, cystinosis, pycnodysostosis, Salla disease / sialic acid storage disease, infantile free sialic acid storage disease, Pompe disease, Danon disease, mucopolysaccharidosis, or cholesteryl ester storage disease.
20. The method of any one of claims 4-11, wherein the disorder is a neurodegenerative disorder.
21. The method of claim 20, wherein the neurodegenerative disorder is any one or more of the disorders listed in Table 2A.
22. The method of any one of claims 4-11, wherein disorder is a neurodevelopmental disorder.
23. The method of claim 22, wherein the neurodevelopmental disorder is any one or more of the disorders listed in Table 3A, any one or more of the CACNA-related neurodevelopmental disorders listed in Table 3B, or any one or more of the CACNA1A- related neurodevelopmental disorders listed in Table 3C.
24. The method of any one of claims 4-11, wherein the disorder is a neurological disorder.
25. The method of claim 24, wherein the neurological disorder is one or more of the disorders listed in Table 4A.
26. The method of any one of claims 4-11, wherein the disorder is cancer.
27. The method of claim 19, wherein cancer is one or more of the cancers listed in Table 5A and / or Table 5B.
28. The method of any one of claims 4-11, wherein the disorder is a defective autophagy disease.
29. The method of claim 28, wherein defective autophagy disease is infectious disease, skeletal muscle disease, systemic lupus erythematosus, or kidney disease.
30. The method of any one of claims 1-29, wherein a total dose of about 1 g to about 10 g of N-acetyl-L-leucine or N-acetyl-L-leucine-2,3,3,4-d4 is administered to the subject per day.
31. The method of claim 30, wherein a total dose of about 1 g to about 8 g of N-acetyl-L- leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered to the subject per day.
32. The method of claim 31, wherein a total dose of about 1 g to about 5 g of N-acetyl-L- leucine or N-acetyl-L-leucine-2,3,3,4-d4is administered to the subject per day.
33. The method of any one of claims 30-32, wherein N-acetyl-L-leucine orN-acetyl-L-leucine- 2,3,3,4-d4is administered once a day, twice a day, or three times a day to the subject to achieve the total daily dose.
34. The method of any one of claims 30-33, wherein N-acetyl-L-leucine or N-acetyl-L-leucine- 2,3,3,4-d4 is administered to the subject as a tablet or as an oral suspension.
35. The method of any one of claims 1-34, wherein N-acetyl-L-leucine or N-acetyl-L-leucine- 2,3,3,4-d4 is administered to the subject in combination with one or more additional therapeutic agents.
36. The method of claim 35, wherein the one or more additional therapeutic agents comprise growth hormone, risperidone, aripiprazole, trofinetide, atomoxetine, guanfacine, clonidine, viloxazine, haloperidol, pimozide, aripiprazole, onabotulinumtoxin A, abobotulinumtoxin A, baclofen, diazepam, tizanidine, dantrolene, baclofen, trihexyphenidyl, L-dopa or carbidopa-levodopa, clonazepam, tetrabenazine, zolpidem, phenobarbital, phenytoin, clonazepam, valproic acid / divalproex sodium, carbamazepine, oxcarbazepine, topiramate, lamotrigine, zonisemide, lacosamide, rufmamide, clobazam, everolimus, cannabidiol, sapropterin hydrochloride, pegvaliase-pqpz, tasimelteon, ganaxolone, acetazolaminde, 4- aminopyridine, fampridine, flunarizine, and / or topiramate.
37. The method of any one of claims 1-36 comprising administering N-acetyl-L-leucine to the subject.
38. The method of any one of claims 1-36 comprising administering N-acetyl-L-leucine- 2,3,3,4-d4 to the subject.
39. A kit for carrying out the method of any one of claims 1-37, the kit comprising N-acetyl- L-leucine and instructions on how to administer N-acetyl-L-leucine to the subject.
40. A kit for carrying out the method of any one of claims 1-36 or 38, the kit comprising N- acetyl-L-leucine-2,3,3,4-d4 and instructions on how to administer N-acetyl-L-leucine- 2,3,3,4-d4 to the subject.
